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Abstract 
Background: Anxiety and depression are psychological conditions that are highly 
prevalent among patients with chronic lung disease. These conditions are associated 
with increased morbidity and, in certain groups, increased mortality. Cognitive 
behaviour therapy (CBT) has shown potential as a treatment of anxiety and depression 
among patients with COPD, asthma and bronchiectasis. Pulmonary rehabilitation has 
the strongest evidence regarding its benefit in these patients, mainly through improved 
physical capacity and education. Consequently, the combination of both treatments 
(CBT and pulmonary rehabilitation) is promising, with potentially enhanced 
therapeutic benefits. The primary aim of this thesis was to determine the impact of 
cognitive behavioural therapy (CBT) as a treatment for patients with chronic lung 
disease and psychological comorbidities undergoing pulmonary rehabilitation. The 
study also assessed risk factors for the presence of anxiety and depression in patients 
attending pulmonary rehabilitation, the effect of CBT on quality of life and, through a 
subgroup analysis, the impact of mild cognitive impairment on CBT. 
Methods: A parallel group, randomised controlled trial (RCT) was conducted, with 
longitudinal follow-up of 12 months. Participants were screened from the pulmonary 
rehabilitation program at The Prince Charles Hospital and recruited if they had Geriatric 
Depression Scale (GDS) ≥4/15 or Geriatric Anxiety Inventory (GAI) ≥3/20, suggestive 
of depression or anxiety, respectively. In addition to pulmonary rehabilitation, the 
Intervention group received CBT comprised by two face-to-face sessions and 4 phone 
sessions, while the Control group received usual care. The main outcome measures 
were GDS and GAI; secondary outcomes were St. Georges Respiratory Questionnaire 
(SGRQ), pulmonary rehabilitation attendance and 6 minute walk test (6MWT).  
Results: The majority of patients attending pulmonary rehabilitation had COPD 
(58.5%), with the remainder having asthma (19.7%), interstitial lung disease (ILD) 
(9%) and bronchiectasis (12.4%). Of the patients screened, 25 (13%) had only 
symptoms of anxiety, 33 (17%) of only depression and 62 (32%) had symptoms of both 
anxiety and depression. Anxiety and depression were strongly correlated with SGRQ 
(p<0.01) and pulmonary rehabilitation program attendance. GDS scores were also 
correlated with 6MWT (p<0.01), past smoking (p<0.01), body-mass index (p<0.01), 
and body-mass index, airflow obstruction, dyspnea, and exercise capacity index 
(BODE) scores (p<0.01); while GAI was not correlated with other parameters.  
65 patients were randomised to the study (24 in the Intervention group, 41 in the Control 
group). Of the 24 patients in the Intervention group, 10 (42%) failed to attend 
pulmonary rehabilitation or withdrew from the study. In the Intervention group, GDS 
significantly improved, compared to baseline, at the end of rehabilitation (mean 
difference -3.1, 95% CI -4.39 to -1.7; P<0.01), 3 months follow-up (mean difference -
1.46, 95% CI -4.17 to -0.75; P<0.01) and 12 months follow-up (mean difference -1.6, 
95% CI -(-3.29 to -0.03; P=0.04). The Control group showed an improvement in GDS, 
compared to baseline, by the end of pulmonary rehabilitation (mean difference -1.34 
95%, CI -2.4 to -0.27; p=0.01) but there was no statistically significant difference at 3 
months (p=0.22) or 12 months (p=0.25) follow-up. There was a no statistically 
significant difference in GDS between Intervention and Control groups at by the end of 
rehabilitation (p=0.053), 3 months (p=0.29) and 12 months (p=0.2) follow-up. There 
was a significant improvement in GAI by the end of rehabilitation in the Intervention 
group (mean difference -2.6, 95% CI -4.69 to -0.57; P=0.01) and the Control group 
(mean difference -2.6, 95% CI -4.16 to -1.14; P<0.01), and no significant difference 
between groups (P=0.9). At 3 months there was no significant improvement in GAI in 
the Intervention group (P=0.07) or the Control group (P=0.14), which continued at 12 
months follow-up for both the Intervention and Control groups (P=0.66) and (P=0.24), 
respectively. There was no statistically significant difference in GAI between groups 
by the end of rehabilitation (p=0.98), 3 months (p=0.59) and 12 months (p=0.74) 
follow-up.  
There was no significant improvement in SGRQ, by the end of rehabilitation, 3 months 
and 12 months follow-up in each of the groups, and no significant difference between 
the Intervention and Control groups. There was no significant improvement in 6MWT 
in the Intervention and Control groups by the end of rehabilitation. There was a 
significant increase in attended pulmonary rehabilitation sessions in the Intervention 
group, compared to the Control group (mean difference 1.59; 95% CI 0.11 to 3.07; 
p=0.03).  
 
 Conclusion: 
In this RCT of patients with chronic lung diseases attending pulmonary rehabilitation, 
there was no evidence found for improved symptoms of anxiety or depression or health-
related quality of life with the addition of cognitive behavioural therapy given in a 
mixed face-to-face and telephone format, compared to usual care. The addition of CBT 
to pulmonary rehabilitation in patients with chronic lung disease was associated with a 
statistically significant ongoing improvement of symptoms of depression up to 12 
months, however this was not significantly more than the Control group. CBT 
completion was associated with better pulmonary rehabilitation attendance; however, 
CBT treated patients had a high withdrawal rate, which may limit its clinical 
applicability. Slower than anticipated recruitment, leading to a smaller than planned 
sample size, and a high dropout rate in the group allocated to CBT may have limited 
the effectiveness of the behavioural intervention approach in this study. The 
improvement of depression scores after pulmonary rehabilitation could be better 
assessed in future larger studies, using treatments that target panic symptoms for 
patients with anxiety and use additional strategies to improve acceptance and adherence 
to psychological interventions by respiratory patients. In conclusion, this current study 
could not demonstrate evidence for the usefulness of CBT for patients with chronic 
lung disease and psychological comorbidities.   
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INTRODUCTION 
Introduction is an updated version of Pumar et al. (1). 
Anxiety and depression are common comorbidities among patients with chronic lung disease. 
The presence of psychological comorbidities among chronic obstructive pulmonary disease 
(COPD) is high, with prevalence ranging from 10% to 57% (2-4) for depression, and from 7% 
to 50% (2, 5, 6) for anxiety. The impact of anxiety or depression in COPD patients is well 
documented and has been shown to be associated with increased mortality (7-9), exacerbation 
rates, length of hospital stay (10-15), and decreased quality of life and functional status (16-18). 
Although the prevalence and impact of psychological comorbidities have been documented 
more extensively for COPD, the limited studies regarding other conditions have shown that 
prevalence is also higher than the average population. For asthma, estimates for major 
depression among persons with asthma varied from 2% to 26% across the surveys, with 
prevalence generally between 5–10% (19). For idiopathic pulmonary fibrosis (IPF), pulmonary 
arterial hypertension (PAH) and bronchiectasis, the prevalence of depression or anxiety have 
been observed to be in the range of 20% to 50% (20-26). In all groups, the concomitant presence 
of psychological comorbidities had a negative impact on quality of life (21, 23, 26-30). 
Although there are well-established interventions targeting anxiety and depression for the 
general population (31), there are limited data regarding the treatment of these conditions in 
patients with chronic lung disease. The only studies performed have been done in COPD 
patients, and these studies have been of varied quality and consequently have a range of results 
(1). Cognitive behavioural therapy (CBT) has shown potential among patients with COPD, 
asthma and bronchiectasis (1, 32-37). Pulmonary rehabilitation has the strongest evidence 
regarding its benefit in these patients, caused mainly through improved physical capacity (38-
40). Therefore, the combination of both treatments is promising, with potentially enhanced 
therapeutic benefit, which would ultimately decrease respiratory symptoms and psychological 
distress in patients with respiratory disease. 
The results of this study will provide data regarding effective treatment for anxiety and 
depression in patients with chronic lung disease. Furthermore, it tests the benefit of a 
multidisciplinary team approach for the treatment of psychological comorbidities in the presence 
of chronic respiratory conditions. 
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This literature review provides an overview of the prevalence, impact and pathophysiology of 
anxiety and depression among patients with chronic lung disease and explores screening tools 
and treatment options. The review will focus on COPD, since the majority of studies have been 
among this population, and they also form the majority of the population attending pulmonary 
rehabilitation. Where information is available for other chronic lung conditions, these data will 
be summarised and discussed. 
 
Prevalence of anxiety and depression as comorbidities in chronic 
lung disease 
COPD has a significant impact on the psychological well-being of people affected. Patients with 
COPD have a higher prevalence of depression and anxiety than the general population (2) and 
COPD patients have a relative risk of 1.69 of developing depression (41). The rates of both 
anxiety and depression may even be more prevalent among COPD sufferers compared with 
other chronic diseases (42).  
The reported prevalence of depression and anxiety are quite varied, depending on the population 
surveyed (smoking status, COPD severity) and the tools used for screening (43). For patients 
with stable COPD in primary care settings or respiratory clinics, the prevalence of depression 
varies widely from 10% to 57% (2, 6), and for anxiety, prevalence ranges from 7% to 50% (2, 
5, 6), with many of these patients being unaware of being affected by either condition (44). 
Risk factors for increased rates of depression include living alone (45) and gender. Females have 
a higher rate of both anxiety and depression (6, 46-48), and rates of depression have shown to 
correlate with severity of dyspnoea as compared with males (47), although the quality of life 
symptoms has not (18). Increasing severity of COPD is associated with higher rates of 
depression and anxiety (4, 9, 49); for example, in patients requiring long-term oxygen, 57% 
were found to have depressive symptoms, and 18% had depression classified as severe (50). 
End-stage COPD patients undergoing palliative care also have high rates of anxiety (51 to 75%) 
and depression (37 to 71%) (42).  
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Other important risk factors for an increased rate of anxiety and depression include patients who 
have been hospitalised for an exacerbation of COPD or recovering from an exacerbation (11, 
51) and severe impairment of physical functioning (5, 6, 45). 
As COPD, other chronic lung diseases show a high prevalence of anxiety and depression 
symptoms. Asthma is historically closely linked to psychiatric diseases and was thought 
previously to be a psychosomatic illness (27). Large cross-sectional studies showed that 
depression is more common in people with asthma (17.3 vs 9.1%) (52) and that having asthma 
increased the chances of having anxiety and depression (odds ratio of 1.5 and 1.6 respectively) 
(19). The prevalence of major depression in asthma varies from 2% to 26% across the surveys, 
with prevalence generally between 5–10% (19), while for anxiety the rate is between 11 and 
37% (53), with even higher rates in those with severe asthma (54). Community-based 
epidemiologic studies in youth and adults demonstrate a strong and consistent association 
between asthma and anxiety disorders (55) with a significant correlation between anxiety and 
asthma severity (56). Concerning interstitial lung disease (ILD), in a mixed ILD cohort, the 
prevalence of anxiety and depression was 31% and 23%, respectively (57). Specificity for IPF, 
the prevalence has been as high as 49% in one study (20). In PAH, the prevalence of depressive 
symptoms ranged from 15.9% to 55.1 (21, 22, 58), while anxiety was between 28% and 45 % 
(21, 58), showing a strong association with the level of functional limitation (22) and quality of 
life (58). For patients with bronchiectasis, 20% to 34% had elevated depression-related scores 
and 38% to 55% had elevated anxiety-related scores (23, 24, 26), also showing significant 
association with poor quality of life questionnaire scores (26).   
Anxiety and depression are highly prevalent comorbidities in patients with chronic lung disease. 
In COPD, multiple risk factors have demonstrated to be associated with the prevalence of these 
comorbidities; however, disease severity seems the most consistent throughout all conditions 
and may represent the psychological toll suffered by patients living with chronic lung disease.  
Pathophysiological mechanisms for anxiety and depression in 
COPD 
Mechanisms for depression: 
The aetiology of the association between depression and COPD is not fully understood; 
however, the relationship is complex and interactive. The most important risk factor for COPD 
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is smoking. Smoking and depression seem to have a complex bidirectional interaction (59). 
Depressed individuals are more likely to smoke (60), and find smoking cessation more difficult 
(60-62). Although the reason to commence smoking is multifactorial with environmental factors 
playing a significant role (63), the presence of depression and anxiety are independent risk 
factors to commence smoking (59, 63, 64) (Figure 1). One possible mechanism for part of the 
increased uptake of smoking is the self-medication hypothesis, where smoking is used as a 
treatment of depressive symptoms (65, 66). Conversely, smokers are more likely to be depressed 
(67) (Figure 1), which could be caused by activation of nicotinic acetylcholine receptors (65), 
or direct inflammatory effects of smoking (68, 69).  
Although smoking could have some part to play as a causative factor for depression, depression 
is still more prevalent among COPD patients than smokers without COPD (48). A possible 
mechanism could be related to ‘overspill’ of local lung inflammation in the circulation (68, 70) 
(Figure 1). It has been speculated that systemic inflammation may play a role in the presence of 
depression (69, 71). Although there are difficulties in the quantification of inflammatory 
markers in the ‘overspill’ theory (68), soluble tumour necrosis factor receptor-1 (sTNFR-1) has 
shown a strong association with rates of depression in COPD patients (70), while tumour 
necrosis factor alpha (TNF-α) showed conflicting results (71, 72). It is not clear if the presence 
of systemic inflammation has a causative association with depression or that it is a marker a 
specific COPD phenotype; such as frequent exacerbators (70).   
Hypoxia is an additional factor that may play a role in the development of depression in COPD 
(Figure 1). Low arterial oxygen saturation has been shown to be associated with periventricular 
white matter lesions (73), which are present in patients with depression (74). However, the 
significance of these findings is contentious since the localisation of subcortical hyperintensity 
in depressed patients has been found to be variable due to different imaging technologies, lesion 
definition and measurement techniques (74, 75).  
Although smoking, inflammation and hypoxia have a potential impact on the prevalence of 
depression in COPD, the strongest predictors of depression among patients with COPD are their 
severity of symptoms and reported quality of life (48) (Figure 1). Functional limitations have 
been similarly shown to mediate depression in other disorders such as arthritis and heart failure 
(76). The amount of perceived instrumental support (the need for assistance for activities of 
daily living) among COPD patients has also been shown to be correlated with depression (77). 
	 12	
 
Figure 1. Mechanisms and relations between smoking and depression 
Mechanisms for anxiety: 
Similarly, to depression, a similar bidirectional interaction is seen between anxiety and smoking.  
Patients with anxiety are more likely to smoke (78); with the self-medication hypothesis and 
vulnerability to peer pressure as possible causes (79). On the other hand, smoking could 
theoretically increase the risk of anxiety thorough nicotine effect on neurotransmitter pathways, 
and through mechanisms similar to COPD; such as ‘overspill’ of local lung inflammation and 
structural brain changes (79).  
Several theories have been proposed to explain the overlap of anxiety and panic attack symptoms 
with COPD (80). Hyperventilation is defined as the exaggerated breathing in excess of metabolic 
need, causing lowering pressure of carbon dioxide (CO2) and causing respiratory alkalosis (81, 
82). This pattern of breathing can cause dyspnoea in healthy individuals and consequently, panic 
attacks in those predisposed patients (82). 
In panic disorder patients, it is possible to evoke symptoms of dyspnoea and chest pain when 
infusing lactate or inhaling excessive CO2 (82). These findings are the basis of the CO2 
hyperventilation model (80). Areas of the brain with intrinsic CO2/H+-sensitive neurons such as 
the ventrolateral surface of the medulla and locus coeruleus are involved in ventilation, but also 
play a role in panic behaviours. The activation of these areas may concomitantly activate 
defensive behaviour and precipitate a panic attack (82).  
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Another relevant theory is the cognitive behaviour model, which is based on the principle that 
normal bodily sensations are misinterpreted by patients with panic disorder and can 
consequently cause a panic attack. This misinterpretation is hypothesized to be secondary to a 
heightened awareness of physiological changes such as dyspnoea and tachycardia (80). A 
behavioural sensitisation event (trauma) may predispose to panic disorders (82), and post-
traumatic stress symptoms are more common in COPD patients with high exacerbation rates 
(83). The exacerbation is likely the sensitizing event, which consequently could lead to more 
exacerbations. 
The pathophysiology of anxiety and depression among COPD patient is complex and poorly 
understood. Patients with depression and anxiety are at higher risk of smoking and find ceasing 
difficult. Likewise, smoking is associated with the development of depression and anxiety. 
Concurrently, the physical, emotional and social impact of COPD is correlated with 
development depression and anxiety. This complex interaction between COPD and mental 
health diseases may cause a self-perpetuating cycle that has a severe impact on a patient’s well-
being.  
 
Association between depression and anxiety symptoms in chronic 
lung disease and morbidity and mortality 
Depression and anxiety are associated with adverse outcomes in patients with chronic lung 
disease. Increased mortality, exacerbations rate and worse quality of life, have all been described 
in COPD patients.  
Effect on mortality: Among COPD patients, depressive symptoms are associated with increased 
mortality among hospitalised (11, 12) and community patients (7-9, 84, 85). Some studies of 
COPD patients have shown an association of anxiety with increased mortality (11-13), whereas 
others have failed to show any association (8). A recent meta-analysis demonstrated that in 
COPD patients, comorbid depression and anxiety were associated with increased risk of 
mortality with relative risks of 2.29 and 1.27, respectively (41).  
Importantly, a prospective study by Divo and colleagues, from the Body-mass index, airflow 
Obstruction, Dyspnoea, and Exercise (BODE) cohort, assessed mortality risk based on the 
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presence of risk factors. This study demonstrated that anxiety among female COPD patients was 
associated with a significant increase in mortality, with a hazard ratio of 13.76. This hazard ratio 
was higher than the risk conferred by coronary heart disease, heart failure, or lung cancer (14). 
The potential causes of this increased mortality with anxiety are probably multifactorial. One 
factor is treatment compliance; for example, patients with anxiety and depression are less 
adherent to medications (86) and are more likely not to complete rehabilitation (87-90). A meta-
analysis has shown that patients with depression and anxiety symptoms are three times more 
likely to be non-adherent to their prescribed medications (91). Alternatively, the presence of 
symptoms of anxiety and depression correlated with disease severity (4, 9, 49) and may occur 
secondary to the impact of this disease on patients well-being and physical capacity; 
consequently, the presence of these comorbidities could be used as another clinical marker of 
disease severity (14). 
Effect on exacerbations: Among COPD patients, exacerbations contribute significantly to 
morbidity and mortality (92). A narrative synthesis of a systematic review of 20 studies has 
shown that depression and anxiety increased the risk of hospitalisation for COPD patients (16). 
A meta-analysis by Laurin et al. showed that the relative risk of in-hospital treated COPD 
exacerbation was 1.12 for depression and 1.18 for comorbid depression and anxiety (93), while 
a more recent study showed a relative risk of 1.94 (15). A large retrospective cohort study 
showed a statistically relevant correlation with between the presence of depression and 
exacerbation with OR of 1.48 (94). Anxiety and depression symptoms were also associated with 
increased in hospital length of stay for COPD exacerbations (11, 95, 96).  
There are multiple possible links between depression or anxiety and increased rates of COPD 
exacerbation. The impact of symptoms of depression and anxiety could place patients at risk 
due to non-adherence with treatment (86, 91), and suboptimal success with smoking cessation 
(11, 93). Depression could have direct effects by impairing the immune system and consequently 
predisposing to infections (97), leading to increased frequency of exacerbations. Worsened 
perception of dyspnoea may lead patients to seek medical attention unnecessarily and increase 
hospital admissions; patients with anxiety and depression during admission have worse 
dyspnoea scores despite having less severe physiological parameters (e.g. pH, partial pressure 
of oxygen and CO2) (98). The meta-analysis by Laurin et al. has shown that patients with anxiety 
were at greater risk for exacerbations that required treatment in the community, whereas those 
with depression were at higher risk for exacerbations requiring treatment in hospital (93). This 
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discrepancy could be explained by “early intervention” among anxious patients that could 
prevent the need for treatment in hospital (93). 
Effect on quality of life: The detrimental impact of COPD on quality of life is well-documented. 
Depression and anxiety symptoms also have a significant impact on quality of life and functional 
status in many chronic diseases (99, 100). In general, patients with depression and anxiety 
perceive their health as poorer than the average population (101). Specifically for COPD, the 
impact of quality of life and functional status is also evident in several studies, independent of 
the severity of COPD or related comorbidities (18, 49, 100, 102-106). A meta-analysis showed 
that the presence of depression and anxiety among COPD patients was one the strongest 
correlations with self-reported health status (107). Comorbid depressive symptoms in patients 
with COPD are associated with persistent smoking (11), increased symptom burden (11), poorer 
physical(108) and social functioning (11), and difficulty in performing daily activities (109) and 
reduced BODE scores (110). Low self-confidence or self-efficacy is also common, which may 
lead to worsened ability to cope with chronic disease (93, 100). Depression is negatively 
associated with acceptance of illness, which could negatively impact patient care and decrease 
treatment compliance (111).  
Depression and anxiety symptoms are associated with increased perception of dyspnoea (98, 
112-114). The presence of psychological symptoms (mainly depression and to lesser extent 
anxiety) has an effect on vital exhaustion, defined as a state characterized by fatigue and lack of 
energy, worsening irritability and feelings of demoralization (115). Fatigue and especially 
dyspnoea are independently negatively associated with poor health status (107, 116).  
The impact of depression and anxiety symptoms are not limited to an individual’s lung disease. 
The presence can influence a person’s end of life decisions (117) or may negatively impact 
partners and their respective relationships (118, 119).  
In patients with asthma, clinical anxiety and panic attacks influence symptom perception and 
asthma management through the effects of anxiety symptoms such as hyperventilation, and 
indirectly through self-management behaviour (27, 28, 120). In patients with PAH, mental 
disorders had a negative impact on quality of life, irrespective of severity of disease (21, 58, 
121). Similar findings were described in bronchiectasis, with anxiety and depression symptoms 
predicting a significantly worse quality of life (23, 26). In interstitial lung disease, the quality of 
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life measure impact depressive symptoms (122), and the presence of depression is significantly 
correlated with dyspnoea symptoms and sleep quality (123).  
Overall, the presence of anxiety or depression have been linked with negative outcomes in 
patients with chronic lung disease. The presence of these comorbidities throughout all conditions 
was associated with worse quality of life and symptoms burden. In COPD patients, the presence 
of these comorbidities are better defined, and of concern, its presence is linked with increased 
exacerbation rate and mortality.  
 
Diagnosis and screening of depression and anxiety 
The gold standard for the diagnosis of depression or anxiety is based on the criteria listed in the 
DSM-IV and achieved through structured interviews performed by a psychiatrist or a clinical 
psychologist. There is a positive relationship between self-reported symptoms and the existence 
of a mental disorder. Therefore, screening instruments that are less costly, faster and easier to 
administer were developed. These screen tools are seen as useful to make the initial evaluation 
of mood disorders, and they can also monitor clinical outcomes of mental health treatments (124, 
125).  
Several screening tools have been validated for use in COPD patients. The Geriatric Depression 
Scale (GDS) and its 15-item short form (GDS-15) are validated as depression tools (126). The 
Geriatric Anxiety Inventory (GAI) has been validated for anxiety in COPD patients (127), while 
the Hospital Anxiety and Depression Scale (HADS) has been validated for both depression and 
anxiety (128). A systematic review showed consistency between tools and that neither 
demonstrated superiority to the other (129). Anxiety Inventory for Respiratory Disease (AIR) 
and Brief Assessment Schedule Depression Cards (BASDEC) are two other scales that have 
been developed exclusively for COPD (5, 130, 131) (Table 1).  For asthma, HADS has been 
validated for anxiety and depression (132), while the Beck Depression Inventory-II (BDI-II) has 
been validated for comorbid depression (133). 
There are concerns regarding the use of screening instruments due to the risk of false positives 
caused by the overlap of symptoms (134), and the uncertainty regarding the impact on routine 
practice (135, 136). Despite the concerns the Global Initiative for Chronic Obstructive Lung 
Disease guidelines recommend that new COPD patients should have a detailed medical history 
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including for anxiety and depression (137), although there is no consensus regarding which 
screening tool is most appropriate for the screening approach for anxiety and depression (138), 
several seem interchangeable (129). 
These tools are useful for screening purposes and have been used extensively to evaluate 
response to therapy. For many of the studies, changes in scores are difficult to interpret as the 
minimal clinically important difference (MCID) has not been established. HADS is one of the 
few tools that the MCID has been established, which was done in the context of patients with 
cardiovascular disease (139) (Table 1).  
Geriatric Anxiety Inventory and Geriatric Depression Scale 
COPD patients are generally older. Therefore, tools that screen for depression or anxiety in 
patients with COPD are likely to be more precise if directed at older individuals. Tools that 
reduce the confounding effects of somatic symptoms have been developed for older groups and 
have been used in patients with chronic medical conditions. GAI was designed in Australia for 
elderly patients. In the study by Cheung et al. (127), GAI was validated for COPD and had a 
slightly better Area under the Curve (AUC) of 0.83 than HADS-A, which was 0.79. Optimal 
cut-off points with GAI score of ≥ 3 had a sensitivity of 85.7%, and a specificity of 78%, while 
the optimal cut-off HADS-A score (≥ 4) had a sensitivity of 78.6%, and a specificity of 70.7% 
(127). In COPD patients, another study showed that HADS-A had a sensitivity of 71% and a 
specificity of 81% while BAI had a sensitivity and specificity of  89% and 62%, respectively 
(140). 
GDS was also designed to determine the presence of depression in older patients. When 
validated for patients with COPD, a cut-off score of ≥ 4 had a sensitivity and specificity of 67% 
and 82%, respectively (126). GDS was more precise than the initial study of HADS-D, which 
showed a sensitivity of 62.1%,  and a specificity of 62.6% and AOC of 0.66 (141). More 
recently, a study by Phan (140) removed a question from the HADS-D score and adjusted the 
cut-off and found an improvement of precision of the test and a new sensitivity of 100% and 
specificity of 82.6%. This same study also assessed the Beck Depression Inventory (BDI-II) and 
determined that with the removal of a specific question and an adjustment of the cut-off the 
sensitivity was now 100% and specificity was 79% (Table 1) 
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Table 1 - Anxiety and depression screening tools for patients with COPD 
Screening 
tool 
Cut-off Sensitivity  Specificity  MCID Validation 
criteria 
References  
Anxiety       
Hospital 
Anxiety and 
Depression 
Scale 
(HADS) 
depression 
subscale 
≥ 4 71 - 78.6% 71 - 81% Yes  MINI (127, 139, 
140) 
 
Beck 
Anxiety 
Inventory 
(BAI) 
≥ 8 89% 62% No MINI (140) 
Anxiety 
Inventory 
for 
Respiratory 
Disease 
(AIR) 
≥ 14.5 80% 75% No MINI (131, 142) 
Depression       
Geriatric 
Anxiety 
Inventory 
(GAI) 
≥ 3 85.7% 78% No MINI (127) 
Hospital 
Anxiety and 
Depression 
Scale 
(HADS) 
depression 
subscale 
≥ 8 
≥ 5 
(Adjusted 
HADS-
D)  
62 - 78% 
100% 
(Adjusted 
HADS-D) 
63 - 81% 
 (82.6%) 
(Adjusted 
HADS-D) 
Yes MINI (139-141) 
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Geriatric 
Depression 
Scale (GDS) 
≥ 4 67% 82% No MINI (126) 
 
Brief 
Assessment 
Schedule 
Depression 
Cards 
(BASDEC) 
≥ 7 100% 93% No GMS (5) 
Beck 
Depression 
Inventory-II 
(BDI-II) 
≥ 7 
≥ 12 
(Adjusted 
BDI-II) 
89% 
100% 
(Adjusted 
BDI-II) 
77% 
79% 
(Adjusted 
BDI-II) 
No MINI (140) 
Table shows validated screening tools for the diagnosis of anxiety and depression in patients 
with COPD. Table shows: cut-off for diagnosis of anxiety and depression, sensitivity and 
specificity of each questionnaire, if each has a determined minimal clinically important 
difference (MCID) and what was the gold standard used for validation.  
 
Treatment approaches for anxiety and depression in patients with 
chronic lung disease 
Depression and anxiety, when coexisting with chronic lung disease, significantly impact quality 
of life and functional outcomes. In acknowledgement of the biopsychosocial impact of chronic 
ill health, the World Health Organization has stated that patients with chronic diseases such as 
COPD should receive integrated care programs which are centred on the patient rather than just 
the disease (143). A similar approach is advocated by the Global Initiative for Asthma (GINA) 
(144). Despite these recommendations, a cross-sectional study of 527 patients with depression 
and COPD, 18.8% of patients were not treated (145). 
Fortunately, interventions targeting these psychological comorbidities are well-established for 
the general population (31, 146).  However, psychological care guidelines are less well 
developed for patients with chronic lung disease (147). Most studies assess the effects of treating 
psychological comorbidities among patients with COPD and typically use treatments based on 
treatment guidelines for depression and anxiety for the broader population (148). These 
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treatments can be divided into pharmacological and psychological interventions (148). 
Psychological therapies used in this population have mainly been those that use elements of 
cognitive and/or behavioural  approaches (146), like relaxation therapy (149) and cognitive 
behavioural therapy (CBT) (150). Other additional therapies for chronic lung diseases have been 
linked with improvement in anxiety and depression, such as self-management strategies (31) 
and pulmonary rehabilitation (38-40).  
 
 
 
 
Psychological therapies 
For patients with a chronic health condition who are also experiencing clinical or sub-threshold 
depression, the UK’s National Institute for Health and Care Excellence (NICE) recommends the 
use of low to high-intensity psychosocial interventions depending on the severity of mood 
symptoms (151). Low-intensity interventions may include individual or self-help programs, or 
online CBT, while high-intensity interventions are typically individual or group CBT sessions. 
These recommendations are based on moderate quality randomised controlled trials and the 
experience and opinion of the Guideline Development Group (151), While the NICE guideline 
targets general chronic health presentations, good quality studies are somewhat lacking for 
specific chronic lung diseases. Most studies are for COPD, and in these existing studies, results 
have been mixed and difficult to compare, due to factors such as: small sample size, varied 
populations, lack of data on disease severity and differences in the screening tools used to assess 
these patients. A meta-analysis has described the benefits of the most common psychological 
interventions - relaxation therapy, CBT and self-management education programs in COPD 
patient (31). However, Cochrane review regarding the impact of psychological interventions in 
COPD and asthma could not draw any firm conclusion regarding its role in treatment (34, 152).    
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Relaxation therapy 
Relaxation therapy aims to promote psychological change through techniques that create a 
relaxed state. Techniques commonly used range from breathing exercises, hypnosis, meditation, 
body positioning, sequential muscle relaxation, mild forms of exercise and visualisation 
techniques (153). These methods are used separately or as an element of other psychological 
treatments or pulmonary rehabilitation (148). 
The effectiveness of relaxation-based therapies for COPD was evaluated in a meta-analysis by 
Volpato et al., which showed slight improvements in symptoms of depression, anxiety and 
quality of life (149).  For patients undergoing a pulmonary rehabilitation program, progressive 
relaxation techniques administered by tape-recorded classes showed a non-significant 
improvement in depression and, to a lesser extent, anxiety symptoms at the time of the end of 
the pulmonary rehabilitation program (154). There have been several smaller studies that have 
investigated other types of relaxation approaches. One small study using tai chi demonstrated a 
non-significant improvement of depression, dyspnoea and physical capacity as measured by six-
minute walk test results (155). A study examining yoga as the intervention showed a significant 
improvement in six-minute walk results and functional performance, non-significant 
improvement in dyspnoea score and quality of life, but no change in anxiety or depression scores 
(156). In these types of studies, it is often difficult to determine whether the benefit is due to the 
physical activity or the relaxation components of the treatment. 
Some consider mindfulness or mind-body breathing therapy as a form of relaxation therapy. It 
uses breathing as a focus point, aiming to increase body and mind awareness and consequently 
reduce stress. In COPD, study results have been mixed. In randomized control trial with patients 
from a veteran hospital with an average age of 67 years, an eight week intervention did not show 
any benefit in terms of symptoms or 6-minute walk test, although there was 41% drop rate on 
the intervention arm (157). A follow-up study by Chan et al., using a similar population and 
similar intervention showed no significant improvement compared to control. However, for the 
group of patients that completed at least six sessions, there was a significant improvement in 
emotional function (158).  
Loosely related to relaxation interventions, singing classes have also been used as an 
intervention in COPD patients. The underlying theory is that singing lessons might improve 
patient quality of life and/or functional status by offering techniques that address both the 
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sensory component of dyspnoea (e.g. control of respiratory pattern to reduce hyperinflation) and 
the affective component (e.g. anxiety and low mood around perceived breathlessness) (159). A 
moderate-sized study employing singing classes showed improvement in anxiety levels and the 
physical component of a quality of life questionnaire (160). In a further study by the same 
researchers, the improvements remained after controlling for the incidental beneficial effects of 
social interaction amongst the participants. (161). Regarding these less traditional interventions, 
there is still a lack of clarity about their applicability, their long-term effectiveness, the active 
component (physical or psychological), and how they may be incorporated into standard care.  
Although it has been shown that relaxation therapy does not improve lung function in asthma 
(162), relaxation therapy has shown benefit in reducing symptoms of asthma in children and 
adults by achieving a significant degree of relaxation, positive attitude, and better yoga exercise 
tolerance. There was also a tendency toward lesser usage of beta-adrenergic inhalers (163). For 
children, relaxation-breathing training combined with a self-management program decreased 
anxiety symptoms (164). In one study, using the  integrated breathing and relaxation technique 
known as the Papworth method, showed a significant improvement in respiratory and anxiety 
symptoms at a 12-month follow-up (165). In regards to mindfulness based treatment, it has 
shown to improve quality of life significantly quality of life but had no impact on lung function 
or control of asthma (166).  
To the best of our knowledge, there are no studies that have examined the effects of relaxation 
therapies among patients with bronchiectasis and IPF. 
The role of relaxation therapy to treat psychological comorbidities in chronic lung disease is still 
unclear due to mixed results. However, certain techniques such as relaxation methods with 
pulmonary rehabilitation, yoga or breathing techniques in asthma have shown promising results.  
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Cognitive behavioural therapy 
CBT is a type of psychotherapy used in the management of a range of psychiatric disorders. It 
is based on an information-processing model in which emotional symptoms are thought to be 
driven by negatively-biased evaluations of the world, the future, or the self (including bodily 
sensations) (167). Performed in collaboration between the therapist and the patient, CBT utilises 
a number of strategies to correct those biased evaluations and provide skills aimed at controlling 
their symptoms and consequently improving the management of their illness (148).  
The use of CBT has gained traction because of its effectiveness in achieving symptomatic relief 
for patients with chronic illnesses (100, 168). In the COPD population, there have been 
numerous studies of varying quality and sample size that have shown promising results (37, 
169-176). A Cochrane review by Pollok et al. (150), shows a small positive effect upon anxiety 
and/or depression scores and inconclusive effects of quality of life; however direct comparison 
is hampered by the fact that interventions varied in regard to the number of sessions, duration 
of each session and delivery format (group or face to face). 
Cost-effectiveness is undoubtedly an important issue, particularly given tightening health 
budgets, and increasing service imperatives to reduce health care spending. One study has shown 
that face-to-face CBT is effective and also may be cost-neutral when implemented in COPD 
patients (168). If other, less expensive approaches are interchangeable to face-to-face, they may 
be more economically attractive.    The use of telephone-based interventions for depression has 
shown to be just as effective as face-to-face (177-179), has shown to be beneficial for patients 
with anxiety and depression associated with other chronic diseases (180, 181) and to be cost-
saving among patients with COPD (182). A recent study evaluating the role of telephone-based 
CBT treatment for anxiety and depression for patients with COPD showed a significant 
reduction in depression but not anxiety symptoms (37).    
A novel alternative approach is the use of an Internet-based intervention, which has been shown 
to be as effective as face-to-face interventions for depression and anxiety (183-185) and maybe 
even useful for patients with cognitive impairment (186). CBT-based therapies, particularly 
tightly manualised therapies for sub-clinical anxiety or depression, may not require a fully 
trained psychologist for its administration, adding to overall cost-effectiveness. A nurse-
administered minimal psychological intervention (MPI), based on the principles of CBT and 
self-management, was used in one study of COPD patients and showed promising results (187). 
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Not all aspects of CBT therapy may be necessary to produce a therapeutic effect. Purely 
behavioural interventions can be as effective as CBT for patients with depression (188). They 
are simpler to administer and theoretically could be used for patients with COPD. A mixed 
approach using elements of meditation may be helpful, Mindfulness-based cognitive therapy 
(MBCT) integrates meditation with elements of CBT. The use of  MBCT, in conjunction with 
pulmonary rehabilitation, demonstrated a durable reduction in psychological distress (189).  
With regards to asthma, studies of CBT are limited. A recent systematic review provided 
tentative support to the use of CBT to reduce anxiety symptoms in asthma; however, a definite 
answer regarding is effectiveness was hindered by the heterogeneity of studies used (190). 
Similarly, a Cochrane review of CBT in asthma was not able to reach any definitive conclusion 
regarding the benefit of CBT in reducing asthma symptoms due to the heterogeneity of studies 
(32-34). A recent feasibility study for patients with comorbid anxiety or depression and severe 
asthma showed weekly face to face CBT was promising, although it was affected by high drop-
out rates (191). 
A small pilot study showed that CBT in patients with bronchiectasis significantly improved 
quality of life scores and psychosocial adjustment (35). To the best of our knowledge, there are 
no studies that have examined the effects of CBT among patients with ILD.  
Despite the heterogeneity of studies, CBT seems to be a promising therapy for patients with 
comorbid psychological conditions and chronic lung disease. Aspects of this psychotherapeutic 
approach, like the possibility of flexible forms of therapy such as telephone and internet-based, 
are additional attractive aspects of this therapy. 
  
 
Self-management strategies  
Self-management programs aim to improve patient care by providing resources and guiding 
health behaviour change in ways that empower the individual. This empowerment is thought to 
increase their ability to carry out medical regimens designed to control their chronic disease, 
improve well-being and decrease exacerbations (192-194). Many self-management programs 
incorporate aspects of CBT.  
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The effects on anxiety and depression of self-management programs for patients with chronic 
health conditions are still unclear, and the results have been modest when compared to more 
specific psychological interventions (31). Jonker et al. found improvement in self-efficacy in 
older people, but no reduction in health care utilisation or improvement in quality of life (192). 
In cardiac patients, one study reported a moderate effect of self-management on functional 
outcomes and depressive symptoms after an acute coronary syndrome (195). For COPD 
patients, although a review by Kaptein et al. reported favourable outcomes for self-management 
on frequency of hospitalisation, greater exercise tolerance and increased quality of life (196), in 
the meta-analysis of 29 RCTs by Coventry et al., there was no overall benefit for self-
management education alone for anxiety and depression in COPD (31).  
A large multicentre randomized trial in COPD patients showed that a self-management 
intervention reduced exacerbation rates (194). Similarly, a Cochrane review by Lenferink et al. 
(197) showed an improvement in quality of life and a reduction in respiratory-related 
hospitalization. However, subgroup analysis showed an increased mortality secondary to a 
respiratory cause in the self-management therapy group. The wide range of measures used across 
the papers surveyed herein reveals the difficulty in both assessing the effectiveness of 
interventions within a study and comparing findings across studies reported in the literature. 
Finally, active participation in decision making and treatment has been suggested to be 
beneficial in the management of chronic diseases. Consequently, interventions such as health 
mentoring (self-management intervention that uses cognitive behavioural techniques to provide 
skills to improve self-efficacy and disease management, and to change unhealthy behaviours) 
(198), would be useful in the management of chronic lung disease. Nursing-based mentoring 
have shown conflicting results with one study showing benefit in quality of life for patients with 
COPD (199), while other studies have failed to show any positive effect on quality of life (200, 
201) or anxiety and depression symptoms (200). Interestingly, increased knowledge gained by 
a mentoring program caused decreased activity in patients with high anxiety and depression 
symptoms and had an opposite effect among patients with fewer symptoms (202).  
A meta-analysis has shown that case management was the least effective intervention for 
reducing anxiety and depression when compared to CBT, relaxation or self-management 
intervention (31). 
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With regards to asthma, self-management interventions have been shown to reduce symptoms, 
health care use and adherence to preventive medication. However, interestingly the use of “stress 
management” techniques was not associated with any symptoms improvement (203). A pilot 
feasibility study has shown that motivational interviewing (a communication style interned to 
increase motivation and confidence in engaging in a particular behaviour) has shown improved 
medication adherence is asthmatics (204).  
For bronchiectasis, a Cochrane review assessing self-management techniques that included 
airway clearance techniques, adherence to therapy, exercise or education had insufficient 
evidence to assess the efficacy of such self-management approaches (205).  
Studies using self-management therapy in patients with chronic disease have demonstrated 
mixed results regarding health care utilization and quality of life. Regarding improving anxiety 
and depression symptoms, so far, self-management therapies have not shown to be beneficial.  
 
Pharmacotherapy 
Pharmacotherapy is a mainstream treatment for anxiety and depression. Although there is some 
controversy regarding effectiveness, meta-analyses have shown the overall benefit of 
pharmacotherapy in the treatment of anxiety and depression (206). In standard clinical practice, 
antidepressants are the first-line medication used for depression and anxiety (146). Other less 
common agents used are benzodiazepines, antipsychotics, anticonvulsants and azapirones (148).  
Antidepressants work by increasing one or multiple synaptic monoamines, dopamine, serotonin 
or noradrenaline. They have similar effectiveness but principally differ based on the type and 
severity of side effects. The main categories are: selective serotonin reuptake inhibitors (SSRIs), 
serotonin and noradrenaline reuptake inhibitors (SNRIs), noradrenaline reuptake inhibitors, 
tetracyclic antidepressants, tetracyclic analogues of mianserin (sometimes called noradrenergic 
and specific serotonergic antidepressants [NaSSA]), tricyclic antidepressants (TCAs), reversible 
inhibitors of monoamine oxidase A (RIMAs), monoamine oxidase inhibitors (MAOIs) and 
melatonergic antidepressants (summarised in Usmani et al. (207)). Antidepressants are a 
moderately effective treatment for depression in healthy individuals, more so in cases of greater 
severity and in melancholia, but there is less certainty in physically ill patients. Among this 
population with subthreshold symptoms of depression (symptoms that are below the DSM-IV 
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criteria for major depression) or mild to moderate depression, NICE guidelines advice that 
antidepressants should not be routinely prescribed (151). A Cochrane review of antidepressants 
(mostly SSRI and TCA), for the treatment of depression or depressive symptoms among 
physically ill patients, demonstrated a significant improvement among patients with depression 
or milder depressive disorder, and a positive trend for depressive symptoms and other depressive 
disorders (208). This Cochrane review also observed that there was a greater long-term 
improvement for SSRIs compared to TCAs. A study assessing the effects of the SSRI, 
fluoxetine, in hospitalized patients with depression, showed a positive trend towards 
improvement of depression symptoms especially for those patients that were more severely ill 
(209).  
In contrast to the wider general population or physically ill, at present, the data for efficacy of 
pharmacotherapy for anxiety and depression are limited for COPD (210). The main studies have 
been of SSRIs and TCAs. SSRIs are the first-line pharmacotherapy treatment for depression and 
anxiety (211). For depression, one moderately large (120 patients) randomized controlled study 
showed that the use of sertraline significantly reduced depressive symptoms and increased 6-
minute walk test (212). While two small studies using paroxetine showed variably significant 
improvement in quality of life questionnaires (213, 214), anxiety and depression scores and 
physical capacity after three months (214). A single-blinded open trial study of 57 COPD 
patients, aiming to assess the acceptability of fluoxetine therapy, showed that over two-thirds of 
patients declined to use fluoxetine therapy, mostly related to patient biases regarding use of 
psychiatric medication (215). Of concern, the SSRIs have been associated with increased 
mortality among older adults with COPD (216).   
For TCAs, several small studies have been conducted in COPD. A study by Borson et al. showed 
that nortriptyline was effective in reducing depressive and anxiety symptoms and in increasing 
physical function (217), although a crossover study of similar size failed to show any benefit 
when using doxepin for patients with symptoms of anxiety and depression (218). In another 
study using protriptyline, the majority of the patients did not complete the trial because of the 
anticholinergic side effects (219). TCAs are no longer first-line treatment for depression or 
anxiety, and consequently, future trials for this medication class are unlikely (220). 
Regarding the treatment of anxiety in COPD patients, a Cochrane review was unable to 
undertake any meta-analysis due to the poor quality of the studies and very small sample sizes 
(207). Only four studies were analysed, with two studies using SSRIs, and the other two using 
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a TCA and azapirones. Two studies using SSRI showed a non-significant reduction in anxiety 
symptoms (207, 214). The studies using TCA and azapirones did not show any improvement 
(218, 221).  
As was the case for psychological treatment, the overall effectiveness of pharmacotherapy for 
anxiety or depression in COPD has not been rigorously tested. Studies in COPD have been 
small, with large heterogeneity of sampling and tools used to assess the efficacy of the 
treatments. In addition, there is limited evidence regarding the impact of side effects of 
pharmacotherapy, such as dry mouth and sexual dysfunction (208). Some side effects of 
treatment (such as dry mouth) may compound adverse effects of medications used for COPD, 
notably the anticholinergic activity of long-acting muscarinic antagonists (222). In addition, 
there are issues regarding patient refusal to take antidepressants due to misconceptions regarding 
depression and addiction, the stigma associated with the disease, and lack of interest and 
motivation (220). Clearly, much more work needs to be done to test pharmacotherapy for anxiety 
and depressive symptoms in COPD and to undertake head-to-head comparisons with 
psychological interventions and combinations of treatments (206). 
Concerning asthma, the use of antidepressants in depressed patients with asthma is an intriguing 
issue. There have been multiple small studies of short duration that have shown a wide range of 
positive effects.  Of these small studies, citalopram has shown decreased steroid use but no effect 
on depressive symptoms (223), while a randomized control study, evaluated the use of twelve 
weeks of treatment with escitalopram for patients with depression. This study showed significant 
improvement in asthma symptoms and corticosteroids use, but only for those with higher 
symptoms severity and that completed the twelve weeks of treatment; however, there was no 
significant improvement in depressive symptoms (224). In regards to anxiety and depressive 
symptoms, the best results were in a small study that used bupropion, which showed significant 
improvement in anxiety and depression symptoms (225). These results are promising regarding 
the effects of antidepressants as a class of medication; however, discordant results for the use of 
antidepressants may be secondary to inherent differences between medications. Adding to this 
complexity, the antidepressant venlafaxine has in fact been reported to cause an asthma-like 
picture, with severe airway obstruction (226).  
As in COPD and asthma, there is a theoretical benefit of antidepressant use for other chronic 
lung diseases such as bronchiectasis, IPF and PAH; however, to our knowledge, there are no 
studies regarding the effectiveness of such medications in these conditions. 
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Pulmonary rehabilitation 
Pulmonary rehabilitation is an essential component of standard care for people who are 
symptomatic from chronic lung diseases, such as COPD, causing breathlessness and functional 
impairment (227, 228). Large observational studies of pulmonary rehabilitation participants 
have reported the prevalence of anxiety symptoms to range between 25% (229) and 40.5%  
(230), and depressive symptoms to range between 17% (229) and 46.7% (230). The symptoms 
of anxiety and depression have been associated with program non-completion (229, 231), 
increased dyspnoea (232), fear of exercise and reduced functional performance both at 
commencement, completion of pulmonary rehabilitation (233, 234) and reduced adherence to 
exercise prescription (230). Furthermore, improvement in the symptoms of depression has been 
associated with improvements in specific domains of health-related quality of life (235). 
However, it is unclear if the symptoms of anxiety and depression should be addressed prior to 
entry to a pulmonary rehabilitation program or during the program.  
Importantly, the symptoms of anxiety and depression have been shown to improve following 
completion of comprehensive pulmonary rehabilitation (38-40). In a large randomised 
controlled trial, participants completing pulmonary rehabilitation were shown to significantly 
improve symptoms of anxiety and depression when compared to the control group of usual care 
(39). Studies have also shown that participants with symptoms of anxiety or depression can gain 
similar improvements in other program beneﬁts arising from pulmonary rehabilitation. For 
instance, in an observational cross-sectional study, individuals with symptoms of anxiety and 
depression had similar benefits in exercise capacity and health-related quality of life following 
pulmonary rehabilitation as participants not experiencing these symptoms (236). Moreover, 
another observational study reported that participants with greater symptoms of anxiety, in fact, 
had a more substantial improvement from exercise training following pulmonary rehabilitation 
(237). Therefore, the recent guideline on pulmonary rehabilitation in adults from the British 
Thoracic Society states that the psychological status of participants is improved with pulmonary 
rehabilitation when compared with usual care, and recommends that individuals with symptoms 
of anxiety and depression should not be excluded from pulmonary rehabilitation (238). The 
addition of psychological therapy could increase the benefit of pulmonary rehabilitation (174, 
189, 239). Two studies have shown that the addition of CBT to pulmonary rehabilitation 
improved 6-minute walk test (6MWT) (175, 240).  
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As for the other chronic lung diseases, accumulating evidence supports the usefulness of 
pulmonary rehabilitation as a treatment. One study in asthma patients has shown that pulmonary 
rehabilitation has shown to significantly reduce symptoms of both anxiety and depression (241). 
With regards to interstitial lung disease, pulmonary rehabilitation as shown short term 
improvement in dyspnoea, quality of life, anxiety and depression scores (242-244); however 
long term effects were not maintained (242). Similar results regarding health-related quality of 
life in bronchiectasis patients were also seen in two studies (245, 246).  
As per the definition by the American Thoracic Society and European respiratory society 
“Pulmonary rehabilitation is a comprehensive intervention based on a thorough patient 
assessment followed by patient tailored therapies that include, but are not limited to, exercise 
training, education, and behavior change, designed to improve the physical and psychological 
condition of people with chronic respiratory disease and to promote the long-term adherence to 
health-enhancing behaviors” (247). Possibly due to the physical improvement or social benefit, 
patients who complete pulmonary rehabilitation have improvement in symptoms of anxiety and 
depression. However, patients with psychological comorbidities have a lower completion rate, 
reduced adherence and worse symptoms. Consequently, there is a possible role of treating 
psychological comorbidities in this population aiming to enhance the benefits of pulmonary 
rehabilitation in this at-risk population. 
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Impact of cognitive impairment 
The presence of cognitive impairment is increased in asthma (248, 249), COPD (250) and ILD 
(251), with possible cause the presence of hypoxemia (249, 250). In COPD patients attending 
pulmonary rehabilitation, the rate of mild cognitive impairment based on MoCA score was 18% 
and 50% if using complete neuropsychological battery (ENB-2) test (252).  
Anxiety is an independent predictor of developing cognitive impairment (253). Depression has 
also been linked with impaired cognition, affecting mnemonic and executive function, 
predominantly set-shifting (a measure of attention and cognitive flexibility) (254, 255). 
Although these psychological comorbidities are associated with cognitive decline, Their impact 
may be modest in increasing the risk of cognitive decline in COPD patients (250). In COPD, 
although the causation has not been clearly defined, the association between depression and 
cognitive decline could be epiphenomenal, possibly related to hypoxemic brain injury (250). To 
determine such association, longitudinal studies would be required. 
What is also unclear is the impact of cognitive deficit in the treatment of anxiety and depression 
(256). Studies have shown conflicting results regarding the impact of cognitive deficits 
(especially executive function) and response to SSRI (256). In a study using neuroplasticity-
based computerized cognitive remediation, a treatment approach with aspects CBT, Marimoto 
et al. (257) showed that patients with executive dysfunction showed a greater reduction in 
depression symptoms than controls without. Another concern is the impact of cognitive deficit 
in other treatments, such as pulmonary rehabilitation. In the study by Cleutjens et al. (258) 
cognitive impairment was associated with lower rates of pulmonary rehabilitation completion; 
however, it did not negatively impact reduction in depressive or anxiety symptoms. 
Cognitive impairment is more common in patients with chronic lung disease and is associated 
with anxiety and depression. The presence of cognitive impairment may impact treatment of 
these comorbidities, and its screening could be useful as a part of the evaluation of patients with 
chronic lung disease.  
 
 
 
	 32	
Conclusion 
Anxiety and depression are common comorbidities among patients with chronic lung disease. 
The presence of symptoms of anxiety and depression are common and have significant impacts 
that adversely affect mortality rate, exacerbation rates, hospital length of stay, quality of life and 
functional status. Pathophysiologically, the mechanism of interaction between psychological 
comorbidities is better understood in COPD, where the interaction is complex and bidirectional, 
with the strongest association being the degree of disease severity and symptoms.      
The gold standard for diagnosis of anxiety and depression is a structured interview. However, 
screening tools are validated tools for the initial evaluation of these comorbidities and are useful 
to assess response to treatment.  Regarding treatment, there is no consensus on how to treat these 
comorbidities. Studies examining specific pharmacological and non-pharmacological treatment 
of these conditions are encouraging, however, limited to small studies of varying quality. Of the 
types of possible treatment, currently, CBT has the most promising results for both COPD and 
asthma, while for other chronic lung condition treatment options have not yet been evaluated. 
While pulmonary rehabilitation is not specifically a treatment for anxiety and depression, 
completion of the program is associated with a reduction in anxiety and depression symptoms. 
Although patients with comorbid anxiety and depression would seem to benefit the most with 
pulmonary rehabilitation, non-completion rate is the highest in this group. 
CBT and pulmonary rehabilitation are the forms of therapy with the strongest evidence to treat 
anxiety and depression in patients with chronic lung disease. The interesting aspect of these 
forms of treatment is that they are possibly complementary, as CBT could be incorporated into 
the pulmonary rehabilitation program and possibly potentiating its effects. This study aimed to 
answer this question. Through a randomized control trial, we aimed to assess the impact and 
feasibility of CBT as a treatment for patients with chronic lung disease and anxiety or depression 
undergoing pulmonary rehabilitation. Results from this study would provide useful data 
regarding the effectiveness of CBT as a treatment for this group of patients, and possibly 
determine if a multidisciplinary approach will be synergistic in the treatment of psychological 
comorbidities in chronic lung disease. 
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Research Plan and Methodology 
Study objectives 
Primary objective: 
The primary objective is to investigate the benefits of CBT used concomitantly with a pulmonary 
rehabilitation program for patients with chronic lung disease and coexisting anxiety and/or 
depression. 
Secondary objectives: 
1. Analyse the screened population and explore associations with anxiety and depression 
by calculating correlations with known risk factors. 
2. Determine the benefits of CBT in improving quality of life in patients attending 
pulmonary rehabilitation program with symptoms of anxiety and/or depression. 
3. Analyse changes in GAI or GDS for only those with an elevated baseline GAI or GDS, 
respectively.  
4. Determine the impact of CBT in improving physical capacity and attendance in patients 
attending pulmonary rehabilitation program with symptoms of anxiety and/or depression 
5. Determine the effect of mild cognitive impairment in relation to symptoms of anxiety 
and depression and change of these symptoms over time. 
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Methodology 
Study design: 
This study was a prospective, two-armed, randomised controlled trial (RCT), with a longitudinal 
follow-up of 12 months. Due to the nature of the therapy, the therapists, and participants were 
not blinded to the conditions. Since the investigator was randomizing, consenting the patients 
and liaising with the psychology department, blinding of the investigator was not possible. Data 
was collected at the end of the pulmonary rehabilitation program, and 3 and 12 months following 
completion of the program for each participant (Figure 2). 
 
  
Figure 2 - Study design 
Patients were randomized 1:1 to intervention or control. Follow-up measurements were taken 
at the end of rehabilitation, 3 months and 12 months post end of rehabilitation 
 
Participants: 
Participants were recruited from the pulmonary rehabilitation program at The Prince Charles 
Hospital. Patients were invited to participate during the first 2 weeks of pulmonary rehabilitation 
(Figure 2).  
  
Intervention - CBT 
Control
Randomization
3 months 12 months
3 months 12 months
8 week pulmonary rehabilitation
Screening
2 weeks
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Recruitment: 
Written informed consent was obtained from all participants prior to enrolling in the study. 
Screening forms were sent before the rehabilitation program commenced. Forms review and 
recruitment were conducted at the completion of the first 2 weeks of the pulmonary 
rehabilitation program. 
Inclusion criteria: 
• Adult patients with thoracic-physician diagnosed COPD, asthma, ILD, or bronchiectasis, 
with consistent symptoms and the following criteria: 
o COPD diagnosis was based on Global Initiative in Obstructive Lung Disease 
(GOLD) spirometric criteria of forced expiratory volume in 1 second (FEV1) < 
80% predicted and FEV1/ forced vital capacity (FVC) <70%. 
o Asthma diagnosis was determined by spirometry with an improvement in FEV1 
of at least 12% and at least 200 mL 10-15 minutes after administration of an 
inhaled rapid-acting β2-agonist, or an improvement in FEV1 of at least 20% and 
at least 200 mL after 2 weeks of treatment with an anti-inflammatory agent such 
as an inhaled corticosteroid or a leukotriene receptor antagonist. 
o ILD diagnosed by thoracic-physician with CT scan, respiratory lung function 
and/or by histopathology. 
o Bronchiectasis diagnosed by thoracic-physician with confirmed high-resolution 
CT scan. 
AND 
• Clinical or subclinical anxiety or depression, defined by GAI score ≥3/20 (127), and/or 
GDS of ≥4/15 (126). 
AND 
• Undergoing a pulmonary rehabilitation program 
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Exclusion criteria: 
• Inability to give written informed consent. 
• Known psychotic disorder. 
• Undergoing psychological therapy  
• Cognitive impairment determined by Mini Mental State Examination (MMSE) score of 
<23 (259, 260) 
• Initially, we excluded patients with a Montreal Cognitive Assessment (MoCA) below 26 
(261). Due to slower than expected recruitment, we undertook an extensive literature 
review and found that there was a lack of studies assessing the efficacy of cognitive 
behaviour therapy for depression and anxiety in patients with mild cognitive impairment, 
while small studies showed that the CBT is feasible (262, 263) in this cohort. Based on 
this finding, we applied to change the protocol to allow patients with mild cognitive 
impairment (normal MMSE and low MoCA) to be eligible, which was approved from 
July 2016.  
o Studies have demonstrated the feasibility of manualized individual cognitive 
behavioural therapy in patients with mild to moderate intellectual disability 
(264). 
o We continued to assess for frontal dementia in the study to assess any possible 
association with poor outcome. 
• Current enrolment in other interventional clinical trials that would potentially interfere 
with this study. 
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Data collection: 
The following data was collected at baseline assessment during enrolment in the study, face-to-
face interview with the participant and review of data from the medical record: 
• Demographics: age, sex, ethnicity, education level, smoking history, living alone 
• Relevant medical history (list of current multi-morbidities) 
• Current medications 
• Respiratory function test results  
• Computed tomography scan, echocardiogram, right heart catheterization, pathology and 
sputum microbiology results (where appropriate, based on the chronic lung disease). 
• 6-minute walk test 
• MMSE score (to exclude cognitive impairment) ranging from 0 to 30 (248). 
• MoCA score (to confirm frontal dementia)(261). 
• Body-mass index (BMI) 
• GDS score (to assess depression) ranging from 0 to 15.  A score of 0 corresponds to no 
symptoms and 15 to maximal symptoms (126).. 
• GAI score (to assess anxiety) ranging from 0 to 20.  A score of 0 corresponds to no 
symptoms and 20 to maximal symptoms (127). 
• Quality of life/symptom scores, specific to each chronic lung disease: 
o SGRQ for COPD, asthma, ILD and bronchiectasis (265-267). 
• Modified Medical Research Council dyspnoea scale (mMRC) (268, 269). 
• The body-mass index, airflow obstruction, dyspnea, and exercise capacity index 
(BODE score) (grading system used as a survival predictor for patients with COPD) 
(270).   
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• Measures of participation during rehabilitation based on participants prescribed exercise 
program based on the American College of Sports Medicine (271). 
o Minimal pulmonary attendance was defined as > 6 sessions (37.5%). 
o Successful pulmonary rehabilitation attendance was defined as > 70% of 
sessions.  
 
Randomisation: 
Patients were enrolled in the study and based on their lung condition stratified and randomised 
on a 1:1: basis to the Intervention group (CBT) or Control group using a computer-generated 
software package (http://www.randomization.com). Based on previous pulmonary rehabilitation 
groups, COPD would likely be unevenly distributed in the study; therefore, we elected to 
randomize patients based on their condition to ensure equal distribution in the Intervention and 
Control groups. There was no specified block size. Patients were informed of their treatment 
group following randomisation, at the time of enrolment in the study. Once randomised, both 
investigators and participants were fully aware of the treatment allocation in an unblinded 
manner, and there was no sham intervention for the usual care. 
 
Intervention: 
The study intervention consisted of CBT conducted by postgraduate psychology interns at The 
Prince Charles Hospital, under the supervision of a qualified psychologist. The intervention 
comprised two face-to-face sessions of 1 hour each, during the period of pulmonary 
rehabilitation, and occurring before or after the sessions. In addition, 4 phone sessions of 45 
minutes each were undertaken for counselling, within the first 2 months after the face-to-face 
sessions. The CBT intervention was tailored to the patient’s individual needs. The use of mixed 
approach with initial face-to-face sessions then telephone-based therapy, was intended to have 
the established face-to-face therapy to improve therapeutic alliance and minimise the possibility 
of reduced effectiveness of a solely telephone-based therapy and then continue with telephone-
based therapy to maximise adherence. 
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 CBT sessions aimed to build skills in self-management, behavioural activation, identifying and 
challenging unhelpful thinking, improving relaxation and breathing skills, and promoting 
effecting coping strategies through training in problem-solving. 
Components of the intervention included: Cognitive interventions: Psychoeducation about the 
interaction between anxiety and physical symptoms (the anxiety-dyspnoea cycle)(272); 
Challenging and modifying unhelpful cognitions; Problem-solving training to address barriers 
to effective coping. Behavioural interventions: Relaxation and distraction techniques; Breathing 
techniques (in conjunction with Pulmonary Rehab team nurses); Reinforcement of activity 
scheduling; Planning and “pacing” skills; Development of a personalised “good coping 
plan”(148, 273, 274) 
The CBT intervention was based on a manualised approach that was developed by the 
Psychology Department of The Prince Charles Hospital. One session was videotaped, and a 
specialist in clinical psychology monitored for adherence to the manual and quality of the 
intervention. 
In addition, as listed below for the Control group, all participants in the Intervention group 
received standard care for their chronic lung disease and undertook a comprehensive 8-week 
pulmonary rehabilitation program (Appendix 1). All participants in the Intervention group 
received a hard copy of the Lung Foundation Australia’s Better Living with COPD patient 
information booklet, which contained a chapter on stress, anxiety and depression (275). 
 
Control group: 
The Control group received standard care for their chronic lung disease and undertook a 
comprehensive 8-week pulmonary rehabilitation with exercise and education (similar to the 
Intervention group). Each week consisted of 2 sessions on (Monday and Friday) of 2 hours 
duration; involving 1 hour of exercise and 1 hour of education. The exercise program consisted 
of a combination of endurance (bike and treadmill/walking) and strength training. Education 
was undertaken as a group and consisted of issues such as: nutrition, medication management, 
management of respiratory conditions, speech therapy, and two sessions given by psychologist 
regarding problem-solving and anxiety and depression in chronic lung disease. All participants 
in the Control group received a hard copy of the chapter on stress, anxiety and depression, from 
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the Lung Foundation Australia’s Better Living with COPD patient information booklet (similar 
to the Intervention group). The investigators provided no cognitive behavioural therapy 
intervention. 
Participants in the Control group received telephone contacts with the study personnel at similar 
times as the Intervention group (i.e. at state times). The telephone call was of shorter duration 
than the Intervention group, lasting 5-10 minutes, and no intervention beyond the assessment of 
symptoms was undertaken.  
 
 
 
Outcome measures 
Primary outcome: 
The primary aim was to assess the efficacy of CBT as an effective treatment of anxiety and 
depression among patients with chronic lung disease attending a pulmonary rehabilitation 
program. GDS and GAI were used to assess depression and anxiety symptoms, respectively. 
These screening tools are validated to screen and monitor clinical outcomes in patients with 
COPD (126, 127). Both GDS and GAI have been validated in older patients. For patients older 
than 65 years of age, GDS with a score of > 4 of the total score of 15 items had a sensitivity of 
67% and specificity of 82% (126). GAI has been validated to determine the presence of anxiety 
symptoms in older patients. In the study by Cheung et al. of a cohort of patients with COPD and 
a mean age of 72,  a cutoff score of >3 of the total score of 20 had a sensitivity of 86% and a 
specificity of 78% (127). At the time of conceptualization of the study, GDS and GAI were the 
most precise tools for screening anxiety and depression in COPD patients. At the time, studies 
using HADS scores demonstrated a low specificity of 62% for depression and 70% for anxiety 
(127, 141). This was thought to lead to an increased susceptibility of enrolling patients with 
falsely elevated anxiety or depression symptoms, which could lead to a reduces capacity of 
distinguishing significant change in symptoms with CBT.  
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Although GDS and GAI tests are not validated for the other conditions, due to the lack of 
validated options for bronchiectasis and ILD and to simplify the protocol we chose to keep these 
tools as markers of anxiety and depression for the non-COPD patients. Changes in symptoms 
were determined by administering GDS and GAI at baseline, end of rehabilitation, 3 months and 
12 months after the end of rehabilitation.  
 
Secondary outcomes: 
• After the study commencement, clinically important difference (MCID) were 
determined for HADS (139) and BDI-II (276), which would have been better tools to 
determine the clinical relevance of the results found. Since GAI and GDS were accurate 
tests in determining the presence of anxiety and depression, respectively, as a secondary 
outcome, we aimed to determine the percentage of patients who achieved normal scores.  
• Assess quality of life by using a validated quality of life questionnaire. SGRQ is a 
validated tool to assess quality of life in COPD patients, asthma, ILD and bronchiectasis 
(265-267). 
• Correlate symptoms of anxiety and depression with other relevant clinical aspects, such 
as: SGRQ, 6-minute walk test, lung function, pulmonary rehabilitation attendance, social 
status, smoking, BMI and BODE. 
• Determine improvement of physical capacity by using a validated marker of physical 
capacity, 6-minute walk distance at baseline and at the end of pulmonary rehabilitation). 
• Pulmonary rehabilitation attendance and participation.  
Initially, we excluded patients with a Montreal Cognitive Assessment (MoCA) below 26 (261). 
After a review of the literature, the presence of mild cognitive impairment was not an excluding 
factor for successful CBT treatment (262, 263). After revision of the protocol, we performed a 
subgroup analysis to determine the impact of mild cognitive impairment upon CBT results.  
	 42	
STATISTICS 
Statistical analysis: 
The analysis was done as an intention to treat. Descriptive statistics were used for exploratory 
analysis. To determine correlation coefficients between continuous variables, Pearson’s 
correlation was used, and for dichotomous variables, a Point-biserial correlation coefficient was 
used. To determine differences between the Intervention and Control groups, paired t-tests and 
c2 tests were undertaken for continuous and categorical outcomes, respectively.  A p-value (two-
tailed) <0.05 was considered statistically significant.  
For data collected at multiple points in time, a longitudinal analysis was undertaken. It involved 
comparing the change in outcomes over time in the Intervention and Control group using 
repeated measures tests. For these paired measures, a Wilcoxon signed-rank test was used to 
determine any significant difference over time. Statistical analyses are run using Stata 17 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
Power calculation:  
Using Stata (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: 
StataCorp LLC), it was calculated that a sample size of 50 intervention and 50 control 
participants has 80% power at alpha (significance) level 0.05 to detect a 3-fold improvement of 
anxiety or depression scores, based on the assumption of improvement 10% of the Control group 
and 33% of the Intervention group.  
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RESULTS 
Screening of patients attending the pulmonary rehabilitation 
program 
Screening: 199 patients attended at least one session of pulmonary rehabilitation between 2 
February 2015 and 23 July 2018 at The Prince Charles Hospital. 193 of these 199 patients were 
screened for symptoms of anxiety and depression as a routine assessment by pulmonary 
rehabilitation program staff. Based on these scores, 120 (62%) had symptoms of either anxiety 
or depression, while 73 (38%) had no symptoms of these.  
Demographics of screened patients: Regarding the demographics of the patients screened, this 
was an older group, with more females than males. The majority of patients had COPD, and the 
remainder had asthma, bronchiectasis and ILD (Table 2). A wide range of lung function 
impairment was observed (Table 2). 87 (45%) patients had a GAI ≥ 3 indicating significant 
symptoms of anxiety, with 25 patients (13%) having only symptoms of anxiety, while 95 (49%) 
patients had a GDS ≥ 4 indicating significant depressive symptoms, with 33 patients (17%) 
having only depressive symptoms. 62 (32%) patients had both symptoms of anxiety and 
depression (Table 1). Anxiety and depression symptoms were prevalent in all conditions, with 
COPD patients having the highest rates (60% for anxiety or depression), while the other 
conditions the prevalence was below 40% (Table 2).  
.  
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Table 2- Demographics of screened patients attending pulmonary 
rehabilitation (n=193) 
 
Characteristics  
Age 70.7 ± 9.4 (40 – 90)  
Gender   
Male 90 (46.6%) 
Female  103 (53.6%) 
No symptoms of anxiety or depression 73 (37.8%) 
Only symptoms of Anxiety  25 (13%) 
Only symptoms of Depression  33 (17%) 
Symptoms of both Anxiety and depression  62 (32.1%) 
Conditions  
COPD 113 (58.5%) 
Asthma 38 (19.7%) 
ILD 18 (9%) 
Bronchiectasis 24 (12.4%) 
Symptoms of anxiety and/or depression per 
condition 
 
COPD  
Only symptoms of Anxiety 7 (6.3%) 
Only symptoms of Depression 16 (14.4%) 
Symptoms of both Anxiety and depression 40 (40%) 
Asthma   
Only symptoms of Anxiety 6 (15.4%) 
Only symptoms of Depression 7 (17.9%) 
Symptoms of both Anxiety and depression 8 (20.5%) 
ILD   
Only symptoms of Anxiety 1 (5.5%) 
Only symptoms of Depression 4 (22.2%) 
Symptoms of both Anxiety and depression 3 (16.7%) 
     Bronchiectasis  
Only symptoms of Anxiety 7 (29.2%) 
Only symptoms of Depression 2 (8.3%) 
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Symptoms of both Anxiety and depression 3 (12.5%) 
FEV1% predicted  
All participants 57.23% ± 24.22 (15 – 129%) 
COPD 47.53 % ± 18.14 (15 – 93) 
Asthma 59.81% ± 21.86 (31 – 129) 
ILD 80% ±19.38 (37 – 107) 
Bronchiectasis 66.33% ± 19.45 (39 – 109) 
6MWT 367.1 ± 100 (49 – 640) 
SGRQ total score 47.2 ± 18.7 (5.48 - 89.7) 
BODE 2.8 ± 2.1 (0 – 9) 
Note: Plus–minus values are means ±SD (standard deviation). Range for continuous variables 
is in brackets. Higher SGRQ scores correlate with worse quality of life. BODE is composed 
of: Body-mass index, airflow obstruction, dyspnea, and exercise capacity index. 
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Correlations between clinical variables in screened patients: Amongst all screened patients, 
there was weak to moderate correlation between symptoms of anxiety and depression and poor 
quality of life based on the SGRQ total score and SGRQ impact scores (which assess social 
functioning and psychological disturbances) (Table 3). Other correlations tested were generally 
weak or not statistically significant (Table 3).   
GDS and GAI were weakly correlated with >70% compliance with pulmonary rehabilitation 
sessions, and the group with <70% attendance rate had significantly higher GAI (p=0.04) and 
GDS (p=0.02).  
There was a weak but statistically significant correlation between failure to attend pulmonary 
rehabilitation (<6 sessions) and GDS (p=0.01) but not for GAI (p=0.09), and patients that failed 
to attend pulmonary rehabilitation had significantly higher GDS scores (p=0.01) but not GAI 
scores (p=0.1).  
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Table 3 - Correlations with anxiety and depression symptoms in screened 
patients (n=193) 
 GDS score P value GAI score P value 
SGRQ total 0.52 <0.01 0.3 <0.01 
SGRQ symptoms 0.26 <0.01 0.21 <0.01 
SGRQ impact 0.52 <0.01 0.31 <0.01 
SGRQ activity 0.4 <0.01 0.16 0.05 
FEV1 % predicted -0.07 0.38 0.04 0.65 
6MWT -0.26 <0.01 0.06 0.42 
Minimum oxygen 
saturation on 6MWT 
0.01 0.86 0.05 0.48 
BMI 0.22 <0.01 0.11 0.15 
BODE index 0.23 <0.01 0.06 0.46 
Smoking      
Current 0.13 0.13 0.01 0.84 
Previous 0.25 <0.01 0.1 0.18 
Pack year 0.14 0.1 0.06 0.46 
Lives alone 0.06 0.37 -0.01 0.82 
Pulmonary rehabilitation 
sessions  
-0.1 0.19 -0.21 <0.01 
Minimal pulmonary 
rehabilitation sessions (>6 
sessions) 
-0.18 0.01 -0.12 0.09  
Pulmonary rehabilitation 
compliance (>70% 
attendance) 
-0.16 0.02 -0.16 0.04 
Pearson’s and Point-biserial correlation were performed continuous and dichotomous variables, respectively. 
Correlation and p value for each group are shown on the table. Higher SGRQ scores correlate with worse quality 
of life. BODE is composed of: Body-mass index, airflow obstruction, dyspnea, and exercise capacity index.   
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Baseline characteristics of patients enrolled 
Of the 193 patients screened, 126 patients were eligible to be enrolled in the study, based on a 
GAI ≥3 and/or GDS ≥4. 22 (17.4%) of these patients declined enrolment in the study, 9 (7.14%) 
did not attend rehabilitation for further assessment, and another 19 (15.07%) were excluded, as 
outlined in the CONSORT diagram (Figure 3). 65 patients were enrolled in the study and were 
randomized (24 patients to Intervention and 41 patients to Control). 10 of 24 patients (41.6%) 
in the Intervention group failed to complete the intervention. Of these 10, 6 patients (25% of the 
Intervention group) withdrew from therapy, and 4 patients (16.6% of the Intervention group) 
failed to attend any CBT sessions and attended further pulmonary rehabilitation sessions.  One 
patient was found not to qualify after review of GAI and GDS. Of those patients who failed to 
attend, there was an average of one session attended. In the Control group, 1 patient withdrew 
(2.4%), 2 patients (4.8%) failed to attend 6 or more pulmonary rehabilitation sessions, and 1 
patient died during the 8 weeks of attendance at pulmonary rehabilitation (Figure 3). 
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Figure 3 - CONSORT participant flow diagram 
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Demographic details: The demographic details of the patients enrolled are described in Table 
4. Similar to the screened patients, COPD was the most common condition. 22% of patients had 
known anxiety and/or depression and 22% were on antidepressants, with SSRI being the most 
common antidepressant. There was no significant difference in antidepressant use between the 
groups (P=0.06).  20% of the population enrolled had a low MoCA score. There were no 
statistically significant differences in parameters between the Intervention and Control groups 
(Table 4).   
 
 
 
Table 4 - Demographics of all patients enrolled and by intervention (n = 65).  
Characteristics  All patients 
(n=65) 
Intervention 
(n=24) 
Control 
(n=41) 
P 
value 
Gender     
Female (n, %) 39 (60%) 12 (50%)  27 (65.85%) 0.27 
Age ± SD (range) 68.8 ± 9.7 (40 – 
86) 
69.6 ± 11.15 (49 
– 86) 
68.5 ± 9.2 (40 
– 85) 
0.65 
Conditions    0.69 
COPD 49 (75.3 %) 20 (83.3%) 29 (70.7%)  
Asthma 7 (10.7%) 1 (4.0%) 6 (14.6%)  
ILD 3 (4.6%) 2 (8.3%) 2 (4.8%)  
Bronchiectasis 6 (9.2%) 2 (8.3%) 4 (9.8%)  
Anxiety     
GAI ≥3 51 (77.8%) 20 (83.3%) 31 (75.6%) 0.68 
Only symptoms 
of Anxiety 
12 (18.4%) 4 (16.6%) 8 (33.3%  
Mean GAI ± SD 
(range) 
7.3 ± 5.6 (0 – 20) 6.7 ± 5.5 (0 – 
20) 
7.4 ± 5.7 (0 – 
20) 
0.63 
Depression     
GDS ≥4 53 (81.5%) 20 (83.3%) 33 (80.49%) 0.6 
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Only symptoms 
of Depression 
14 (21.5%) 4 (16.6%) 10 (24.3%)  
Mean GDS ± SD 
(range) 
6.1 ± 3.3 (0 – 15) 6.5 ± 3.3 (0 – 13) 5.8 ± 3.3 (0 – 
15) 
0.46 
Symptoms of 
both Anxiety and 
depression 
39 (60.0%) 16 (66.6%) 23 (56.0%)  
6MWT (m) 362.2 ± 118.7 338.4 ± 114.8 376.1 ± 118.6 0.23 
BODE 3.0 ± 2.3 3.1 ± 2.3 2.8 ± 2.4 0.72 
SGRQ baseline  50.2 ± 19.3 56.5 ± 16.9 0.18 
Previously 
diagnosed anxiety 
or depression 
15 (23.0%) 3 (17.6%) 12 (37.5%) 0.15 
Only Anxiety 2 (14.3%) 0 2 (18.2%)  
Only Depression 7 (50.0%) 1 (33.3%) 6 (54.5%)  
Both Anxiety 
and depression 
5 (35.7%) 2 (66.7%) 3 (27.3%)  
Antidepressants  2 13 0.06 
SSRI 8 (53.3%) 2 6  
SNRI 4 (26.6%) 0 4  
TCA 3 (20.0%) 0 3  
MMSE 29.06 ± 0.99 (26 
- 30) 
29.2 ± 0.8 (28 – 
30) 
29 ± 1.1 (26 – 
30)  
 
MoCA 26.6 ± 2.1 (20 – 
30) 
26.3 ± 2.4 26.7 ± 1.9 0.49 
MoCA (<26) 13 (20.0%) 4 (16.6%) 9 (21.9%)  
Notes: *Significant, p<0.05.   
The demographics of the Intervention group and Control group are expressed separately. T-test was undergone to 
determine the significance of the difference. There was no statistically significant difference between groups. 
Higher SGRQ scores correlate with worse quality of life. Higher GAI and GDS correlate with more symptoms of 
anxiety and depression receptively. Higher BODE scores correlates with increased mortality in COPD patients. 
Percentages may not add to 100% due to rounding. 
 
	 52	
Outcomes at the end of the pulmonary rehabilitation program 
Within groups: At the end of pulmonary rehabilitation, there was a statistically significant 
decrease (improvement) in anxiety (GAI) and depression scores (GDS) compared to baseline, 
for each of the Intervention and Control groups (Table 5). There was no statistically significant 
difference in quality of life (SGRQ) scores.  
Between groups: There was no statistically significant difference in the changes in GAI or GDS 
scores between the Intervention and Control groups (Table 6). The waterfall plot of changes of 
scores for individual patients shows that GDS improved for almost all patients that attended 
CBT, which was not the case of the control patients (Figure 4).  
Patients with high symptom scores at baseline: For those patients with symptoms of 
depression at baseline (GDS score ≥4/15), there was a significant improvement in GDS by the 
end of rehabilitation, within each of the Intervention (p<0.01) and Control groups (p=0.01)  
(Table 7), which was not statistically different between these groups (p=0.16). The median GDS 
score was 5; when considering response of treatment in patients with GDS above this cut-off, 
there were significant improvements within both the Control (p=0.03) and Intervention (p<0.01) 
groups, but no significant difference in changes of scores between the groups (p=0.058). 
For patients with symptoms of anxiety at baseline (GAI score ≥3/20), there was a significant 
improvement in GAI by the end of rehabilitation, within each of the Intervention (p=0.01) and 
Control groups (p<0.01) (Table 8), which was not statistically different between these groups 
(p=0.16). When analysing patients above the median GAI score (GAI ≥ 6), there was a 
significant reduction of this score within both the Control and Intervention groups, with no 
significant difference between the groups (p=0.42).  
For SGRQ, there was no significant improvement in GAI and GDS scores for both Control and 
Intervention groups (Table 6). If assessing SGRQ for those patients with an elevated baseline 
GDS or GAI, there was also no significant improvement SGRQ after rehabilitation (Table 6 and 
Table 7).  
6MWT and attendance: 58% of patients had an improvement in 6MWT after pulmonary 
rehabilitation. However, there was no overall significant improvement from baseline for either 
the Control or the Intervention group (Table 5), with waterfall plot showing a similar distribution 
of change the control and CBT groups (Figure 4). The Intervention group showed a significant 
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increase in the number of sessions of pulmonary rehabilitation attended, with the average 
number of attended sessions in the Intervention group being 14.0 (± 1.7) while in the Control 
group was 12.4 (± 2.6) (diff = 1.59; 95% CI, 0.11 to 3.07; p = 0.03). 
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Table 5 - Within-group analyses showing changes in GDS, GAI, SGRQ and 6MWT scores in the Intervention and 
Control groups. 
End point 
(n=14) 
Intervention  
Median (IQR) 
Patien
ts  
Difference (95% CI) 
from baseline 
P value Control 
Median (IQR) 
Patien
ts  
Difference (95% CI) 
from baseline 
P value 
GDS         
Baseline 5.5 (4 – 10)  19   5 (4 – 8) 37   
End of 
rehabilitation 
3 (1 – 5) 19 -3.1 (-4.39 to -1.7)  <0.01 4 (1 – 7) 37 -1.3 (-2.4 to -0.27)  0.01 
3 months 4 (3 – 5) 15 -1.46 (-4.17 to -0.75) <0.01 5 (3 – 8) 37 -0.6 (-1.31 to 0.28) 0.22 
12 months 3.5 (2.5 – 5.5) 12 -1.6 (-3.29 to -0.03)  0.04 5 (2 – 8) 29 -0.5 (-1.41 to 0.38)  0.25 
GAI         
Baseline 7.5 (3 – 8.5) 19   7 (3 – 12) 39   
End of 
rehabilitation 
3 (0 – 6) 19 -2.6 (-4.69 to -0.57) 0.01 3 (0 – 8) 39 -2.6 (-4.16 to -1.14)  <0.01 
3 months  2 (0 – 8) 15 -1.6 (-5.1 to 0.31) 0.07 5 (2 – 11) 39 -0.8 (-2.5 to 0.2)  0.14 
12 months 5 (1.5 – 11) 12 -0.9 (-4.98 to 3.31)  0.66 3 (2 – 11) 29 -1.1 (- 3.2 to 0.84) 0.24 
SGRQ         
Baseline 49.7 ± 18.5 19   59.8 (43.8 - 68.6) 37   
End of 
rehabilitation  
53.8 (32.9 - 64.8) 19 -6.35 (-17.34 to 4.63)  0.24 52.4 (37.0 - 61.5) 35 -6.0 (-14.84 to 2.84) 0.17 
3 months 44.8 (29.4 – 59.5) 13 -3.8 (-15.12 to 7.4) 0.47 51.7 (38.9 – 62.9) 32 -5.6 (-15.33 to 4.04) 0.24 
12 months 45.9 (32.8 – 61.2) 11 4.2 (-11.52 to 20) 0.56 50.2 (30.5 – 63.5) 27 -8.2 (-19.35 to 2.93)  0.14 
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6MWT         
Baseline 320 (266 – 430) 19   375 (307 – 465)  32   
End of 
rehabilitation  
339.5 (255 – 427) 19 - 3.4 (-24.4 to 16.6)     0.7 382.5 (300 – 459)  32 14.7 (-5.7 to 35.1) 0.15 
An intention-to-treat analysis was performed using a paired t-test to determine change over time.  P values compared anxiety, depression and quality of life questionnaires 
at End of rehabilitation, 3 and 12 month follow-up, with Baseline. Higher SGRQ scores correlate with worse quality of life. Higher GAI and GDS correlate with more 
symptoms of anxiety and depression receptively. Significant P values (<0.05) were bolded.   
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Table 6 - Group analyses  showing between Intervention and Control groups for GAI, GDS and SGRQ scores, at the 
End of rehabilitation, 3 months and 12 months.   
End point 
(n=14) 
Intervention 
group  
Difference from 
baseline  
Median (IQR) 
Number 
of 
patients 
Control group  
Difference from 
baseline  
Median (IQR) 
Number 
of 
patients 
Intervention 
difference - Control 
difference (95% CI).  
Between 
group 
compariso
n P value 
GDS end of rehabilitation  -3 (-5 to 0) 19 -1 (-3 – 0) 37 -1.7 (-3.45 to 0.13)  0.053 
GDS 3 months follow-up -1 (-2.5 – 0) 12 -0 (-3 – 0) 35 -0.7 (-2.2 to -0.68) 0.29 
GDS 12 months follow-up -1 (-4 – 1) 11 -0.5 (-2 – 1) 26 -1.2 (3.01 to 0.66) 0.2 
GAI end of rehabilitation 0 (-7 – 1) 19 -1.5 (-6 – 0) 38 -0.1 (-2.5 to 2.55)  0.98 
GAI 3 months follow-up 0 (-5.5 – 1.5) 12 0 (-3 – 2) 37 -0.8 (-3.43 to 1.93)  0.59 
GAI 12 months follow-up -2 (-5 – 3) 11 -2.5 (-4 – 1) 26 0.1 (-4.21 to 4.47) 0.74 
SGRQ end of rehabilitation  -6.8 (-21.2 - 14.3) 19 -5.6 (-26.9 - 13.3) 35 0.3 (-14.51 to 13.8) 0.96 
SGRQ 3 months follow-up -0.29 (-16.0 - 13.4 12 -11.7 (-28.8 – 4.9) 29 -4 (-13.5 to 21.5) 0.64 
SGRQ 12 months follow-up 5 (-21.1 - 19.3) 10 -7.9 (-19.8 - 12.6) 24 -8.7 (12.54 to 30.1) 0.06 
An intention-to-treat analysis was performed using an independent t-test between the Intervention and the Control groups at the End of rehabilitation, 3 months and 12 months 
follow. Up. Higher SGRQ scores correlate with worse quality of life. Higher GAI and GDS correlate with more symptoms of anxiety and depression receptively. Significant P 
values were bolded.
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Figure 4 - Waterfall charts demonstrating changes of GAI, GDS, SGRQ and 6MWT in 
each individual patient that attended cognitive behavioural therapy and Control 
groups before and after pulmonary rehabilitation. 
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Table 7 - Within-group analyses showing changes in GDS and SGRQ scores for only patients with elevated GDS at 
baseline and the percentage that reached normal GDS scores.  
End point Intervention 
(n=14) 
 
Difference (95% 
CI) compared to 
baseline 
P value Control (n=37) 
 
Difference (95% 
CI) compared to 
baseline 
P 
value 
GDS (patients with GDS ≥4) Median (IQR)   Median (IQR)   
Baseline 6 (4 - 10)   6 (4 - 10)   
End of rehabilitation (n = 62) 4 (2 -5) -3.3 (-4.74 to - 1.84)  <0.01 5 (2 – 8) -1.7 (-3.0 to -0.3) 0.01 
3 months (n = 44) 4 (3 - 5) -2.6 (-4.4 to -0.83) <0.01 5.5 (3 – 8) -0.8 (-1.76 to 0.15) 0.09 
12 months (n = 32) 4 (3 - 5)  -1.7 (-3.66 to 0.26) 0.08 7 (4 – 8) -0.5 (-1.75 to 0.70) 0.38 
SGRQ (for patient GDS≥4)  (Mean ± SD)   (Mean ± SD)   
Baseline 46.5 (28.28 – 64.8)   60.5 (37.77 – 69.86)   
End of rehabilitation (n = 62) 45.5 (42.65 – 61.27)  0.55 54.3 (45.37 – 64.53)  0.63 
3 months (n = 44) 50.6 (34.92 – 61.78)  0.93 53.88 (39.53 – 64.40)  0.60 
12 months (n=32) 64.8 (52.91 – 71.24)  0.14 53.3 (38.44 – 71.42)  0.63 
Patients achieving normal 
GDS (GDS <4) 
Number (%)   Number (%)   
End of rehabilitation (n = 43) 10/18 (55.5%)   10/30 (33.3%)   
3 months (n = 42) 9/17(52.9%)   9/31 (29%)   
12 months (n = 32) 4/10 (40%)   5/21 (23.8%)   
An intention-to-treat analysis was performed using a paired t-test to determine change over time.  P values compared depression and quality of life questionnaires at 
End of rehabilitation, 3 and 12 month follow-up, with Baseline. Patients with a normal GDS at baseline were excluded from the analysis.  Significant P values 
(<0.05) were bolded.   
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Table 8 - Within-group analyses showing changes in GAI and SGRQ scores for only patients with elevated GAI at 
baseline and the percentage that reached normal GAI scores.   
End point Intervention 
(n=14) 
 
Difference (95% 
CI) compared to 
baseline 
P 
value 
Control (n=37) Difference (95% CI) 
compared to baseline 
P 
value 
GAI (for patient GAI≥3) Median (IQR)   Median (IQR)   
Baseline 7.0 (3.5 – 8.5)   9 (5 – 15)   
End of rehabilitation (n = 62) 4.0 (0.5 – 7) -3.3 (-5.86 to -0.79) 0.01 5 (3 – 11) -3.37 (-5.29 to – 1.46) <0.01 
3 months (n = 44) 5.5 (3.0 – 8.5) -2.7 (-5.9 to 0.37) 0.07 6.5 (4 – 11) -1.63 (-3.31 to 0.04) 0.06 
12 months (n = 32) 5.0 (1 – 13) -1.6 (-7.36 to 4.03) 0.51 6 (2 – 12) -1.47 (-4.03 to 1.08) 0.24 
SGRQ (for patient GAI≥3)        
Baseline 52.3 (28.28 - 64.64)    63.5 (48.50 - 72.13)   
End of rehabilitation (n = 62) 43.6 (26.86 – 59.61)  0.27 53.95 (36.10 – 64.77)  0.13 
3 months (n = 44) 42.6 (30.74 – 60.64)  0.32 52 (39.53 – 61.08)  0.22 
12 months (n = 32) 56.9 (52.22 – 71.12)  0.68 52.1 (26.93 – 69.80)  0.23 
Patients achieving normal 
GAI (GAI<3) 
Number (%)   Number (%)   
End of rehabilitation (n = 41) 6/16 (37.5%)   7/29 (24.1%)   
3 months (n = 40) 8/15 (53.3%)   5/30 (16.6%)   
12 months (n = 30) 2/9 (22.2%)   6/23 (26.1%)   
An intention-to-treat analysis was performed using a paired t-test to determine change over time.  P values compared anxiety and quality of life questionnaires at 
End of rehabilitation, 3 and 12 month follow-up, with Baseline. Patients with a normal GAI at baseline were excluded from the analysis.  Significant P values 
(<0.05) were bolded.   
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Outcomes at 3 months follow-up 
Within groups: At 3 months follow-up after the end of pulmonary rehabilitation, there 
were 50 patients assessed. Of those, 13 patients (26%) were in the Intervention groups, 
and 37 (74%) were in the control group. There was a sustained improvement in GDS 
in the Intervention group (p < 0.01) that was not demonstrated in the Control group 
(Table 5) (Figure 5). There was no statistically significant improvement in GAI (Figure 
5) and SGRQ from baseline in both the Intervention and Control groups (Table 5). 
Between groups: At 3 months, there was no statistically significant improvement in 
GDS,  GAI and SGRQ scores between the Intervention and the Control groups (Table 
6). 
Patients with high symptom scores at baseline: Analysing GDS change for those 
with elevated GDS at baseline, there was a sustained improvement in scores at 3 months 
follow-up in the Intervention group (p<0.01), which was not demonstrated in the 
Control group (p=0.09) (Table 7); and there was no significant difference between 
groups (p=0.3). Patients with an elevated GDS did not demonstrate a significant 
improvement in SGRQ by 3 months.  
For patients with an elevated GAI score at baseline, there was no significant 
improvement in GAI in the Intervention group (p=0.07) and the Control group 
(p=0.06)(Table 8); which was not significantly different between the groups (p=0.13). 
There was no significant improvement SGRQ at 3 months follow-up in this population, 
in both Intervention and Control groups (Table 8). 
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Outcomes at 12 months follow-up 
Within groups: At 12 months follow-up after the end of pulmonary rehabilitation, there 
were 38 patients assessed. Of those 9 patients (23.7%) were in the Intervention groups, 
and 29 (76.3%) were in the control group. There was a sustained improvement in GDS 
in the Intervention group (p = 0.04) that was not demonstrated in the Control group 
(Table 5) (Figure 4). There was no statistically significant improvement in GAI (Figure 
5) and SGRQ from baseline in both the Intervention and Control groups (Table 5). 
Between groups: At 12 months follow-up, there were no statistically significant 
differences in the changes in GAI, GDS and SGRQ scores between the Intervention 
and Control groups (Table 6). 
Patients with high symptom scores at baseline: For patients with an elevated GDS, 
there was no significant sustained improvement in scores at 12 months follow-up in the 
Intervention group (p=0.08) and the Control group (p=0.38) (Table 7); There was no 
significant difference between the Intervention and Control Groups (p=0.48). For those 
with an elevated GDS, there was no significant improvement in SGRQ in this group at 
12 months for both the Intervention and control groups (Table 7). 
For patients with an elevated GAI, there was no significant improvement in GAI at 12 
months for both the Intervention and Control groups (Table 8), which was not 
significantly different between the groups (p=0.84). There was no significant 
improvement in SGRQ in both Intervention and Control groups, for those with an 
elevated GAI (Table 8).  
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Figure 5 - Box plot graph of Geriatric Anxiety Inventory (GAI) and Geriatric 
Depression Scale (GDS) over time. 
Graph A shows a box plot with GDS over time. Graph B shows a box plot with GAI over 
time. Underneath are the number of patients analysed in each group at each follow-up time.  
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Impact of mild cognitive impairment 
There were 13 patients (20%) with a MoCA consistent with mild cognitive impairment 
(score of <26). Of these, 4 patients received CBT. At the end of rehabilitation, patients 
with mild cognitive impairment failed to demonstrate an improvement in GDS, GAI 
and SGRQ (p=0.61); while the patients with a normal MoCA had an improvement in 
GDS (p<0.001), GAI (p<0.001) but not for SGRQ (p=0.08) (Table 8). There was no 
significant difference in GAI (p=0.39), GDS (p=0.19) and SGRQ (p=0.79) between 
those with low MoCA and those with normal MoCA. 
At 3 and 12 months follow-up after the end of pulmonary rehabilitation, there were 10 
patients with a low MoCA score. At 3 months follow-up, there was no significant 
difference in GDS and SGRQ. While those with a normal MoCA score, there was an 
improvement in GDS (p=0.01), and GAI (p<0.001) but not for SGRQ (p=0.08) TTable 
8).  There was no significant difference in GAI (p= 0.66), GDS (p=0.95) and SGRQ 
(p=0.31) between those with low MoCA and those with normal MoCA. 
At 12 months follow-up after the end of pulmonary rehabilitation, there was no 
significant difference for GDS, GAI (p=0.46) and SGRQ for those with a low MoCA 
score. Patients with a normal MoCA demonstrated a sustained improvement of GDS 
(p=0.02) and  GAI (p=0.01) but not for SGRQ (p=0.38) (Table 8). There was no 
significant difference in GAI (p= 0.66), GDS (p= 0.95) and SGRQ (p=0.31) between 
patients with low and normal MoCA at 12 months follow-up. 
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Table 8. Within-group analyses of GAI, GDS and SGRQ overtime for patients with mild cognitive impairment and a 
patients without mild cognitive impairment. 
End point 
(n=14) 
 Low MoCA 
(N=13) 
Difference (95% CI) P value Normal MoCA 
(N=52) 
Difference (95% CI) P value 
GAI Median (IQR)   Median (IQR)   
Baseline 6 (4 – 8)    7 (3 – 12.5)   
End of rehabilitation 5 (2 – 9.5) -1.6 (-4.7 to 1.53) 0.28 3 (0 – 7) -2.9 (-4.23 to -1.63)  <0.001 
3 months  6.5 (2 – 11) -0.5 (-2.91 to 1.91) 0.65 4.5 (1 – 9) - 2.9 (-4.23 to - 1.63)  <0.001 
12 months 9.5 (3 – 13) 1.8 (-3.49 to 7.09)  0.46 3 (1 – 10) -2 (-7.75 to - 3.33) 0.02 
GDS       
Baseline 6 (4 – 7)    5 (4 – 10)   
End of rehabilitation 5 (3 – 7) -0.7 (-2.54 to 1.04)  0.37 3 (1 – 5) -2.2 (-3.18 to -1.25)  <0.001 
3 months 4.5 (2.5 – 7.5) -0.6 (-2.23 to 0.89) 0.36 4 (3 – 7) -1.2 (-2.05 to -0.27) 0.01 
12 months 6 (2 – 8) -0.3 (-2.73 to 2.13)  0.78 4 (2 – 7) -1 (-1.8 to -0.26)  0.01 
SGRQ (Mean ± SD)   (Mean ± SD)   
Baseline 53.7 ± 19.22   54.7 ± 17.8   
End of rehabilitation  50.13 ± 14.9 -13.7 (- 18.76 to 11.64)  0.61 47.9 ± 18.66 -6.8 (-14.53 to 0.97) 0.08 
3 months 55 ± 14.56 2.8 (-12.77 to 18.39) 0.69 46.7 ± 19.1 -7.2 (-15.66 to 1.25) 0.09 
12 months 58.7 ± 10.78 5.5 (-10.55 to 21.52) 0.45 49.1 ± 22.8 -7.7 (-18.56 to 3.08)  0.15 
Paired t-test was performed to determine change over time.  P values compared anxiety, depression and quality of life questionnaires at End of rehabilitation, 3 
and 12 month follow-up, with Baseline. Higher SGRQ scores correlate with worse quality of life. Higher GAI and GDS correlate with more symptoms of 
anxiety and depression, receptively. Significant P values (<0.05) were bolded.   
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Discussion 
Overview of results  
This study did not show a significant improvement in GAI, GDS or SGRQ scores when 
comparing CBT added to pulmonary rehabilitation or pulmonary rehabilitation alone. 
There was a large proportion of patients with anxiety and depression among patients 
attending pulmonary rehabilitation. GDS was correlated with poor quality of life, 
6MWT, BMI and not FEV1, while GAI was only correlated with poor quality of life. 
Depression was also correlated with poor attendance. By the end of pulmonary 
rehabilitation, there was an improvement in GAI and GDS independent of treatment. In 
the Intervention group, GDS was lower than baseline at 3 and 12 months, which was 
not the case for the Control group. However, there was no significant difference in GDS 
between the Intervention and Control groups even when only analysing those with an 
elevated GDS at baseline. The improvement in GAI seen at the end of rehabilitation 
was not present at 3 or 12 months for both Intervention and Control groups. There was 
no significant improvement in SGRQ at any point during the study for patients 
receiving or not CBT. Sub-group analysis of a small number of patients with mild 
cognitive impairment showed no improvement in GDS and GAI at any follow-up point. 
There was a significant increase in attended pulmonary rehabilitation sessions in the 
Intervention group, compared to the Control group. 
 
Screened population  
Incidence of anxiety and depression symptoms 
In our study, patients attending pulmonary rehabilitation demonstrated a high incidence 
of anxiety (44%) and depression symptoms (48%). COPD was the largest cohort, and 
the incidence of anxiety in this subgroup was 42%, while depression was 50%, which 
was somewhat higher than previous studies of similar patients (88, 230). The high 
incidence of psychological comorbidities in the rehabilitation group likely reflects 
patients with severe and symptomatic disease, which are generally the reasons that 
prompted a referral to pulmonary rehabilitation in the first instance. Because of the high 
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incidence of neuropsychological impairment and the impact of these comorbidities on 
these patients; routine screening before pulmonary rehabilitation may be a beneficial 
step in the optimization of treatment in these patients.   
 
Correlations between anxiety and depression symptoms and other clinical 
variables 
Our study showed a correlation between higher GAI and GDS scores and impaired 
quality of life, which has been similarly demonstrated in previous studies (102, 107). 
Although the severity of COPD has been associated with rates of anxiety and depression 
(9, 40), we did not find a consistent correlation between physiological markers of 
COPD severity and anxiety or depression symptoms.  
In contrast to a previous study, anxiety and depression were not correlated with living 
alone (277). We did find an expected correlation between tobacco history and 
depression. Although epidemiological studies have been heterogeneous, they have 
generally found an increased risk of anxiety among patient with a previous or current 
history of nicotine use (78), which was not demonstrated in our group. This finding 
could be secondary to other factors (such as quality of life and shortness of breath 
symptoms) playing a more significant role in the development of anxiety symptoms 
among patients with severe lung disease. 
Anxiety symptoms were not correlated with 6MWT distance, level of oxygen saturation 
during 6MWT, severity of lung disease based on FEV1 or BMI. The only significant 
correlation with anxiety was with quality of life, as assessed by the SGRQ. The 
perceived impact of the disease, the possible trauma associated with the presence of a 
severe lung disease and life-threatening events associated with exacerbations of these 
conditions (83), may play a more significant impact on the psychological well-being of 
patients with respiratory conditions than the physical impact of these respiratory 
conditions.  
6MWT and BMI but not FEV1 were correlated with depression symptoms. These 
correlations have been demonstrated in a previous study (40), and interestingly, a 
reduction in body fat mass after rehabilitation was associated with improvement in 
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depression symptoms (40). This association could be bidirectional in nature, as 
depression is associated with decreased activity leading to elevated BMI, but also an 
elevated BMI is associated with increased inflammation which could lead to depressive 
symptoms (68). Anxiety, depression and quality of life reflect the negative impact of 
chronic lung disease on each patient’s psychosocial well-being. This impact is not 
trivial, and all three are associated with increased mortality (14, 16, 269). Consequently, 
screening for anxiety and depression, similarly to quality of life, maybe an important 
aspect in prognostication of patients with chronic lung disease. 
 
Impact of anxiety and depression symptoms and pulmonary rehabilitation 
attendance 
Similar to previous studies, the presence of depression was associated with poor 
pulmonary rehabilitation attendance and completion (87-90, 231). Non-attendance to 
rehabilitation programs may reflect poor overall compliance and adherence to other 
forms of treatment, as depression has been associated with poor medication compliance 
(91). The cause is unclear, but lack of energy, motivation and poor perception of self-
worth could all contribute to the lack of engagement to treatment in this population. 
This is unfortunate since due to the negative impact of anxiety and depression and the 
positive effects of pulmonary rehabilitation for these patients, they are a group who 
could benefit the most from engagement with treatment. 
 
Treatment effects 
Effects of pulmonary rehabilitation on anxiety and depression symptoms 
This study evaluated the effects of CBT as an addition to pulmonary rehabilitation for 
patients with chronic lung conditions of moderate to severe severity and symptoms of 
anxiety and depression. As demonstrated in previous studies (40, 278, 279), there was 
a significant reduction in symptoms of anxiety and depression in all patients at the end 
of pulmonary rehabilitation.  However, in contrast to those studies, there was no 
improvement in SGRQ. The study by Catalfo et al. (40), similarly to our study, was 
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directed at patients with symptoms of anxiety and depression but involved an intensive 
rehabilitation program of 2 hours daily for 6 weeks, which is significantly more than 
the 2 hours twice of week undertaken by our pulmonary rehabilitation program. This 
significantly more intensive exercise protocol could explain the marked improvement 
in both quality of life and mood symptoms in the study and highlights the link between 
physical capacity and mood. Our study showed that despite the lack of improvement in 
SGRQ, there was an improvement in anxiety and depression symptoms, which may 
indicate that these symptoms are more responsive to the effects of exercise and 
rehabilitation.  
Our study used GAI and GDS to screen and determine improvement. This may impact 
the interpretation of our findings, as the clinical implications of changes in scores have 
not been determined. At the time of devising this study, GAI and GDS were considered 
to be more specific than HADS (127, 141) and were used in our hospital, therefore were 
chosen as outcomes in this study. More recent studies have since shown that after some 
alteration in HADS-D scores, it has become a more precise test (140). Added to the fact 
that HADS scores have now a validated MCID, HADS is the most validated test for the 
screening and assessing improvement of anxiety and depression in patients with chronic 
lung disease and may be a better option for future studies.  
 
 
Effects of CBT on depression 
As demonstrated in previous studies (174, 175), our study showed a significant 
improvement in GDS by the end of rehabilitation for both the Control and Intervention 
group; however, the Intervention group seemed to have a larger although modest 
reduction in mean GDS of 3.1 (almost 50% of baseline score) compared to the Control 
group (1.34) and although there was a trend it did not reach statistical significance (p = 
0.053). Interestingly, there was an overall improvement in GDS in almost all patients 
that attended CBT, while the control group showed that approximately 2/3 of the 
patients improved (Figure 4). The improvement pattern in those that attended CBT was 
similar to changes found in GAI and SGRQ for both Intervention and Control groups. 
After CBT, the level of reduction of depression scores in our study was similar to the 
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study by Catalfo et al. (40) which had a more intensive rehabilitation program, which 
may indicate that CBT could augment the psychological benefits of pulmonary 
rehabilitation. A factor that could have contributed to the lack of significance between 
Control and Intervention groups by the end of rehabilitation was the overall 
improvement in all patients, which could have been secondary to the physical 
improvements caused by rehabilitation. Another factor that may have been relevant is 
the possible effects of psychological teaching during rehabilitation. However, this was 
modest in our rehabilitation program - entailing a 1-hour session in problem-solving, 
and a basic education session regarding the association of anxiety and depression with 
chronic lung disease (Appendix 1). The dampening effect of pulmonary rehabilitation 
may have been present in another recent similar study, which used 6 sessions of group-
based CBT given with a similar pulmonary rehabilitation program (175). Our study had 
an intention-to-treat analysis that may have also had a dampening effect in assessing 
improvement in GDS, caused by the significant withdrawal rate in the study. 
Our study showed a sustained improvement in GDS at 3 and 12 months, which did not 
reach significance at 3 months and 12 months follow-up. The lack of significant 
difference due to the reduced sample size analysed, especially at 12 months, causing a 
type 2 error. Another compounding effect was the intention-to-treat analysis that in a 
cohort with a high dropout rate could underestimate the change due to CBT. This 
demonstrates that CBT could have an effect in prolonging pulmonary rehabilitation 
benefits in patients with symptoms of depression, a fact supported by the demonstration 
of sustained improvement of GDS between baseline and follow-up for the Intervention 
group but not for the Control group.  
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Effects of CBT on Anxiety 
With regards to anxiety symptoms, the Intervention and Control groups had very similar 
results with a significant improvement in the score by the end of rehabilitation that did 
not sustain to 3 and 12 months. The reason for the lack of sustained improvement in 
GAI or the discrepancy between anxiety and depression was not clear, although similar 
results were demonstrated in a comparable study that used mindfulness and CBT added 
to pulmonary rehabilitation (189). Possible reasons for the heterogeneity of results are: 
different methods of anxiety symptoms assessment tools (175), durations of CBT, 
method of delivery of therapy or if CBT was aimed at panic symptoms or generalized 
anxiety. There have been mixed results regarding therapy delivery and duration and 
improvement in anxiety and depression scores. A study by Hynninen et al. (170) 
showed sustained improvement in both depression and anxiety, although the study 
involved 7 sessions of 2 hours of group delivered CBT, which is significantly more 
than our protocol of 6 sessions with 2 face to face and 4 phone delivered sessions. On 
the other hand, a study by Farver-Vestergaard et al. (189) using mindfulness-based 
CBT provided 8 telephone sessions and 8 group sessions added to pulmonary 
rehabilitation and showed a reduction in depression symptoms but not anxiety. The 
study by Livermore et al. (173) which had a targeted protocol to panic-related anxiety 
symptoms given to post-pulmonary rehabilitation patients, showed a significant 
reduction in anxiety score up to 18 months post treatment, although there was no change 
in depression scores. This may imply that the cognitive behaviour model of panic 
disorders could be an important factor in the development of anxiety in patients with 
chronic lung disease (80). Targeted therapy (aimed at panic-related anxiety) such as: 
approaches that target misinterpretation of normal bodily sensation, education 
regarding the cycle of panic anxiety in COPD and breathing technique such as “pursed 
lip breathing’’ (173); maybe more important than the number of sessions attended. 
Different measures of anxiety may have a confounding effect when comparing different 
studies, as they may possess differences in sensitivity or precision in measuring changes 
over time. As an example, a study by Luk et al. (175) did not demonstrate an 
improvement in anxiety symptoms when using HADS but did when using the 
Depression Anxiety Stress Scale (DASS), indicating that tools like HADS are less 
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sensitive or that tools such as DASS are having a false-positive effect due to the overlap 
of depression symptoms and symptoms secondary to a chronic disease (134). 
 
 
Effects of CBT to 6 minute walk test and pulmonary rehabilitation attendance. 
 
We did not demonstrate an improvement in 6MWT in either Intervention or Control 
groups. However, there was an improvement during pulmonary rehabilitation of 58% 
of the patients. This is similar to previously reported results from our rehabilitation 
program, which showed a response rate between 56% and 58% of participants (280, 
281), and is similar to other studies that have shown response between 47% and 67% 
of participants (231, 282). Other pulmonary rehabilitation programs with more sessions 
have shown greater 6MWT improvement (40, 278, 279). The study by Luk et al. (175) 
used a similar pulmonary rehabilitation program as our study and did not show an 
improvement in 6MWT for the control group, however in this study, 6 sessions of 
group-based CBT was associated with an improvement in 6MWT. 
Symptoms of anxiety and depression correlate with reduced attendance rate at 
pulmonary rehabilitation programs (88, 231), and the presence of symptoms of 
depression is the strongest correlate to poor treatment adherence (230). As anticipated, 
this study showed that targeted psychological therapy with CBT was associated with 
improved attendance at pulmonary rehabilitation. In our cohort, the improved 
attendance did not translate to improved physiological markers such as 6MWT or 
improved SGRQ. Nevertheless, improved attendance may have had a psychological 
benefit to the intervention group, as pulmonary rehabilitation completion has been 
associated with improvement in anxiety and depression symptoms (39).  
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Impact of cognitive impairment 
A quarter of our patients (n=13) had mild cognitive impairment based on MoCA scores. 
In our small subgroup analysis, these patients did not respond significantly to 
pulmonary rehabilitation, oppose to patients without cognitive impairment, although 
there was no significant difference between the groups. This finding differs from a 
previous larger of study by Cleutjens et al. (258) which showed that the presence of 
cognitive impairment did not impact pulmonary rehabilitation, although their program 
was longer and went from 8 to 14 weeks. Although the subgroup analysis is limited, 
and the small numbers could have caused a lack of identifiable improvement, other 
reasons for the discrepancy with a previous study (258) was not obvious. It is possible 
that patients with cognitive impairment may require a more extended rehabilitation 
program to demonstrate improvement in anxiety and depression symptoms and 
education sessions may have reduced impact on these patients. Commonly in COPD 
patients with cognitive impairment, there is an impairment in executive function and 
cognitive flexibility, areas that are essential to implement new techniques and strategies 
that are learnt in pulmonary rehabilitation. Consequently, an extended pulmonary 
rehabilitation program or the addition of other approaches, such as CBT may be 
beneficial. The impact of CBT among these patients is unclear, but studies have been 
encouraging among this group in reducing symptoms of anxiety and depression (257). 
Patients with cognitive impairment have shown decreased attendance rate to pulmonary 
rehabilitation (258); in our study, CBT improved attendance, which may be beneficial 
in this population with a more reduced attendance rate.    
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Limitations  
The main limitation in our study was slower than expected enrolment and high rates of 
withdrawal or failure to attend therapy, leading to a relatively small number of patients 
completing the Intervention arm. In the Intervention arm, 10 of 24 patients (42%) 
withdrew or did not attend pulmonary rehabilitation and CBT. Compared to another 
study that had only employed telephone-based CBT (37) this is a lower than expected 
completion rate. 31% of patients approached to the study declined therapy before 
receiving any CBT, which could reflect pre-conceptions of what CBT entails and its 
effectiveness, or the stigma associated with psychological conditions. The addition of 
CBT to pulmonary rehabilitation treatment could be seen by some as cumbersome, 
although in general, patients that did not attend CBT also failed to attend pulmonary 
rehabilitation. It is possible that solely telephone-based therapy would have fewer 
withdrawals, which would make it a more attractive method of additional CBT therapy.  
The final number of participants was approximately two-thirds of the total number 
originally planned, due to limited resources available, and the slower than anticipated 
recruitment rate (plus the high dropout rate from the Intervention group). Therefore, a 
decision was made to end the study at 65 randomised participants. The study did not 
use block randomization, and unfortunately, there was a disproportionate number of 
patients randomized to the Control group of the study early in the randomization 
process. The disproportionate number of patients randomized into the Control group 
and the high withdrawal rate in the Intervention group led to an unbalanced study. 
Follow-up results at 12 months were also restricted, due to a reduction in human 
resources (e.g. retirement of the research nurse involved in the study and the primary 
investigator moving interstate to undergo specialization training) and only the data of 
41 patients were acquired. The small number of patients at 12 months would make the 
analysis more susceptible to type 2 error, where we would fail to demonstrate a 
difference when there truly was one. The high withdrawal rate could also have led to a 
selection bias in the study, although this was mitigated by the intention to treat analysis. 
CBT seems to improve depression scores, but possibly only to patients already 
predisposed to engage in treatment, as shown in the waterfall plot. Independent of this 
matter, offering CBT to patients with depression during pulmonary rehabilitation would 
be beneficial, even if only to those willing to participate.  
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The study was a pragmatic approach for all patients, independent of their underlying 
condition undergoing pulmonary rehabilitation. This approach was chosen based on the 
hypothesis that an integrated pulmonary rehabilitation program with psychological 
treatment would benefit all patients. Although there was no difference in between 
groups, it is possible that psychological comorbidities are different between pulmonary 
conditions and consequently require different approaches, an aspect that was not 
assessed in our study.  
 
Future considerations 
Improvement in depression scores in the CBT group indicates the possible benefit in 
adding this treatment to patients with depressive symptoms attending pulmonary 
rehabilitation. Patients have the opportunity to learn strategies to manage depressive 
symptoms like cognitive restructuring and have opportunities to practice those 
techniques during safe and supervised exposures that cause dyspnoea. The pulmonary 
rehabilitation sessions can create positive experiences, improve acceptance and has the 
potential for desensitization of shortness of breath. How much teaching or how many 
sessions are sufficient to achieve proficiency in deploying these strategies is not clear; 
however, more sessions are likely to improve the likelihood of success (170, 172, 174). 
The target of therapy could play an essential role in the improvement of anxiety 
symptoms, as possibly the addition of therapy more directed at panic attack related 
anxiety be more beneficial to those with anxiety symptoms (173). More intensive 
pulmonary rehabilitation programs are also likely to be more effective to improve mood 
symptoms (40), and in this context, the addition of CBT can lead to more opportunities 
to employ learnt strategies and possibly be a more effective treatment. Other options 
for rehabilitation such as home rehabilitation (283) are possibly as effective as usual 
pulmonary rehabilitation, making telephone-based CBT an ideal additional therapy for 
this form of rehabilitation. Another aspect that needs clarification is which method of 
delivery is the most efficient and cost-effective; as face-to-face may be more effective 
for anxiety symptoms (173), while telephone-based therapy may have better patient 
engagement (37).  
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Conclusions 
In conclusion, this randomized control trial of mixed face-to-face and telephone-
delivered CBT versus usual care, in patients undergoing pulmonary rehabilitation, 
found no difference in depression, anxiety and quality of life symptoms at the end of 
pulmonary rehabilitation. There was an associated sustained but modest improvement 
in depressions scores at 3- and 12-months follow-up in the Intervention group, which 
was not demonstrated in the Control group. The addition of CBT to pulmonary 
rehabilitation did not improve anxiety and quality of life symptoms compared to 
pulmonary rehabilitation alone at 3- and 12-months follow-up. The use of CBT did 
improve pulmonary rehabilitation attendance, although this did not translate into an 
improvement in psychological or physical markers. A subgroup analysis of patients 
with mild cognitive impairment based on reduced MoCA scores showed that the 
effectiveness of pulmonary rehabilitation was reduced. This study was limited by the 
high withdrawal rate in the intervention arm, which impaired the power of the study 
and may limit the clinical application of this form of CBT in this group. Overall, in this 
study, the use of CBT did not demonstrate a significant improvement in psychological 
parameters by the end of rehabilitation or at 12 months follow-up. Although suggestive 
for improvement in depression symptoms, this study could not demonstrate evidence 
for the usefulness of CBT for patients with chronic lung disease and psychological 
comorbidities. 
Future studies should assess the effect of CBT on depression symptoms in this 
population with larger studies; better determine the effect of targeted therapy against 
panic attack related anxiety for those with anxiety symptoms and assess the difference 
in face-to-face therapy or telephone-based CBT in this population.  
  
	 76	
References 
1. Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and 
depression-Important psychological comorbidities of COPD. Journal of thoracic 
disease. 2014;6(11):1615-31. 
2. Hynninen KM, Breitve MH, Wiborg AB, Pallesen S, Nordhus IH. 
Psychological characteristics of patients with chronic obstructive pulmonary disease: 
a review. J Psychosom Res. 2005;59(6):429-43. 
3. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. 
Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. 
Chest. 2005;127(4):1205-11. 
4. Raherison C, Ouaalaya EH, Bernady A, Casteigt J, Nocent-Eijnani C, Falque 
L, et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med. 
2018;18(1):117. 
5. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly 
outpatients with chronic obstructive pulmonary disease: prevalence, and validation of 
the BASDEC screening questionnaire. Int J Geriatr Psychiatry. 2000;15(12):1090-6. 
6. Xiao T, Qiu H, Chen Y, Zhou X, Wu K, Ruan X, et al. Prevalence of anxiety 
and depression symptoms and their associated factors in mild COPD patients from 
community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 
2018;18(1):89. 
7. de Voogd JN, Wempe JB, Koeter GH, Postema K, van Sonderen E, Ranchor 
AV, et al. Depressive symptoms as predictors of mortality in patients with COPD. 
Chest. 2009;135(3):619-25. 
8. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. Sex, 
depression, and risk of hospitalization and mortality in chronic obstructive pulmonary 
disease. Archives of internal medicine. 2007;167(21):2345-53. 
9. Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. 
Chest. 2010;137(2):341-7. 
10. Bhatia A, Prakash V, Kant S, Verma AK. A search for covert precipitating 
clinical parameters in frequent exacerbators of chronic obstructive pulmonary disease. 
Lung India. 2016;33(6):600-4. 
11. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and 
chronic obstructive pulmonary disease: effect on mortality, hospital readmission, 
	 77	
symptom burden, functional status, and quality of life. Archives of internal medicine. 
2007;167(1):60-7. 
12. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW. Acute exacerbations of 
chronic obstructive pulmonary disease and the effect of existing psychiatric 
comorbidity on subsequent mortality. Psychosomatics. 2011;52(5):441-9. 
13. Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, 
depression and living alone in chronic obstructive pulmonary disease. Qual Life Res. 
2002;11(4):309-16. 
14. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. 
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary 
disease. American journal of respiratory and critical care medicine. 2012;186(2):155-
61. 
15. Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Alseda M, 
et al. Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr 
Care. 2018;54(3):398-404. 
16. Pooler A, Beech R. Examining the relationship between anxiety and 
depression and exacerbations of COPD which result in hospital admission: a 
systematic review. International journal of chronic obstructive pulmonary disease. 
2014;9:315-30. 
17. Cox A, Anton C. Safety profile of bupropion for chronic obstructive 
pulmonary disease. Lancet. 2001;358(9286):1010. 
18. Lee H, Jhun BW, Cho J, Yoo KH, Lee JH, Kim DK, et al. Different impacts of 
respiratory symptoms and comorbidities on COPD-specific health-related quality of 
life by COPD severity. Int J Chron Obstruct Pulmon Dis. 2017;12:3301-10. 
19. Scott KM, Von Korff M, Ormel J, Zhang MY, Bruffaerts R, Alonso J, et al. 
Mental disorders among adults with asthma: results from the World Mental Health 
Survey. Gen Hosp Psychiatry. 2007;29(2):123-33. 
20. Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic 
pulmonary fibrosis. Chronic respiratory disease. 2013;10(3):127-33. 
21. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. 
Anxiety and depression disorders in patients with pulmonary arterial hypertension and 
chronic thromboembolic pulmonary hypertension. Respir Res. 2013;14:104. 
	 78	
22. Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al. Anxiety and 
depression in patients with pulmonary hypertension. Psychosom Med. 
2004;66(6):831-6. 
23. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, et al. 
Depression and anxiety symptoms in bronchiectasis: associations with health-related 
quality of life. Qual Life Res. 2013;22(3):597-605. 
24. Giron Moreno RM, Fernandes Vasconcelos G, Cisneros C, Gomez-Punter 
RM, Segrelles Calvo G, Ancochea J. Presence of anxiety and depression in patients 
with bronchiectasis unrelated to cystic fibrosis. Archivos de bronconeumologia. 
2013;49(10):415-20. 
25. Carvajalino S, Reigada C, Johnson MJ, Dzingina M, Bajwah S. Symptom 
prevalence of patients with fibrotic interstitial lung disease: a systematic literature 
review. BMC Pulm Med. 2018;18(1):78. 
26. Gao YH, Guan WJ, Zhu YN, Chen RC, Zhang GJ. Anxiety and depression in 
adult outpatients with bronchiectasis: Associations with disease severity and health-
related quality of life. Clin Respir J. 2018;12(4):1485-94. 
27. Jain A, Lolak S. Psychiatric aspects of chronic lung disease. Curr Psychiatry 
Rep. 2009;11(3):219-25. 
28. Deshmukh VM, Toelle BG, Usherwood T, O'Grady B, Jenkins CR. Anxiety, 
panic and adult asthma: a cognitive-behavioral perspective. Respiratory medicine. 
2007;101(2):194-202. 
29. Tomioka H, Imanaka K, Hashimoto K, Iwasaki H. Health-related quality of 
life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal 
study. Internal medicine. 2007;46(18):1533-42. 
30. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: Clinical 
impact and management. Respirology. 2017;22(4):651-61. 
31. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, et al. 
The effect of complex interventions on depression and anxiety in chronic obstructive 
pulmonary disease: systematic review and meta-analysis. PLoS One. 
2013;8(4):e60532. 
32. Put C, van den Bergh O, Lemaigre V, Demedts M, Verleden G. Evaluation of 
an individualised asthma programme directed at behavioural change. The European 
respiratory journal. 2003;21(1):109-15. 
	 79	
33. Ross CJ, Davis TM, MacDonald GF. Cognitive-behavioral treatment 
combined with asthma education for adults with asthma and coexisting panic disorder. 
Clinical nursing research. 2005;14(2):131-57. 
34. Yorke J, Fleming SL, Shuldham CM. Psychological interventions for adults 
with asthma. The Cochrane database of systematic reviews. 2006(1):CD002982. 
35. Parkin CL, Margereson C, McLoughlin B, Hawking R, Fleming S. A pilot 
study of the effects of a specialist nurse-led cognitive-behavioural therapy service on 
coping, respiratory function and quality of life for patients with bronchiectasis. 
Journal of clinical nursing. 2006;15(6):782-4. 
36. Kew KM, Nashed M, Dulay V, Yorke J. Cognitive behavioural therapy (CBT) 
for adults and adolescents with asthma. Cochrane Database Syst Rev. 
2016;9:CD011818. 
37. Doyle C, Bhar S, Fearn M, Ames D, Osborne D, You E, et al. The impact of 
telephone-delivered cognitive behaviour therapy and befriending on mood disorders 
in people with chronic obstructive pulmonary disease: A randomized controlled trial. 
Br J Health Psychol. 2017;22(3):542-56. 
38. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation 
improves depression, anxiety, dyspnea and health status in patients with COPD. Am J 
Phys Med Rehabil. 2007;86(1):30-6. 
39. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et 
al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a 
randomised controlled trial. Lancet. 2000;355(9201):362-8. 
40. Catalfo G, Crea L, Lo Castro T, Magnano San Lio F, Minutolo G, Siscaro G, 
et al. Depression, body mass index, and chronic obstructive pulmonary disease - a 
holistic approach. Int J Chron Obstruct Pulmon Dis. 2016;11:239-49. 
41. Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between 
clinically relevant depression or anxiety and COPD: a systematic review and meta-
analysis. Chest. 2013;144(3):766-77. 
42. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in 
far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and 
renal disease. J Pain Symptom Manage. 2006;31(1):58-69. 
43. Matte DL, Pizzichini MM, Hoepers AT, Diaz AP, Karloh M, Dias M, et al. 
Prevalence of depression in COPD: A systematic review and meta-analysis of 
controlled studies. Respiratory medicine. 2016;117:154-61. 
	 80	
44. Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Alseda M, 
et al. Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr 
Care. 2018. 
45. van Manen JG, Bindels PJ, Dekker FW, CJ IJ, van der Zee JS, Schade E. Risk 
of depression in patients with chronic obstructive pulmonary disease and its 
determinants. Thorax. 2002;57(5):412-6. 
46. Dowson C, Laing R, Barraclough R, Town I, Mulder R, Norris K, et al. The 
use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic 
obstructive pulmonary disease: a pilot study. N Z Med J. 2001;114(1141):447-9. 
47. Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et 
al. Anxiety and depression in COPD patients: The roles of gender and disease 
severity. Respiratory medicine. 2006;100(10):1767-74. 
48. Hanania NA, Mullerova H, Locantore NW, Vestbo J, Watkins ML, Wouters 
EF, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary 
disease cohort. American journal of respiratory and critical care medicine. 
2011;183(5):604-11. 
49. Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, Blanc PD, et al. 
Depression and health-related quality of life in chronic obstructive pulmonary disease. 
The American journal of medicine. 2009;122(8):778 e9-15. 
50. Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and 
depression in patients with severe oxygen-dependent chronic obstructive pulmonary 
disease. J Cardiopulm Rehabil. 2001;21(2):80-6. 
51. Andenaes R, Kalfoss MH. Psychological distress in hospitalized patients with 
chronic obstructive pulmonary disease. European journal of epidemiology. 
2004;19(9):851-9. 
52. Weatherburn CJ, Guthrie B, Mercer SW, Morales DR. Comorbidities in adults 
with asthma: Population-based cross-sectional analysis of 1.4 million adults in 
Scotland. Clinical and experimental allergy : journal of the British Society for Allergy 
and Clinical Immunology. 2017;47(10):1246-52. 
53. Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: Current 
evidence and clinical evaluation. Allergy. 2017. 
54. de Carvalho-Pinto RM, Cukier A, Angelini L, Antonangelo L, Mauad T, 
Dolhnikoff M, et al. Clinical characteristics and possible phenotypes of an adult 
severe asthma population. Respiratory medicine. 2012;106(1):47-56. 
	 81	
55. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJ, Goodwin RD, 
Kubzansky L, et al. Anxiety disorders and comorbid medical illness. General hospital 
psychiatry. 2008;30(3):208-25. 
56. Katon W, Lozano P, Russo J, McCauley E, Richardson L, Bush T. The 
prevalence of DSM-IV anxiety and depressive disorders in youth with asthma 
compared with controls. J Adolesc Health. 2007;41(5):455-63. 
57. Holland AE, Fiore JF, Jr., Bell EC, Goh N, Westall G, Symons K, et al. 
Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung 
disease. Respirology. 2014;19(8):1215-21. 
58. Yorke J, Deaton C, Campbell M, McGowen L, Sephton P, Kiely DG, et al. 
Symptom severity and its effect on health-related quality of life over time in patients 
with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respir 
Res. 2018;5(1):e000263. 
59. Chaiton M, Cohen JE, Rehm J, Abdulle M, O'Loughlin J. Confounders or 
intermediate variables? Testing mechanisms for the relationship between depression 
and smoking in a longitudinal cohort study. Addict Behav. 2015;42:154-61. 
60. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. 
Smoking, smoking cessation, and major depression. JAMA. 1990;264(12):1546-9. 
61. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the 
course of major depression: a follow-up study. Lancet. 2001;357(9272):1929-32. 
62. Audrain-McGovern J, Leventhal AM, Strong DR. The Role of Depression in 
the Uptake and Maintenance of Cigarette Smoking. Int Rev Neurobiol. 2015;124:209-
43. 
63. Lim KH, Chong Z, Khoo YY, Kaur J. Parental smoking status, stress, anxiety, 
and depression are associated with susceptibility to smoking among non-smoking 
school adolescents in Malaysia. Asia Pac J Public Health. 2014;26(5 Suppl):81S-90S. 
64. Fergusson DM, Lynskey MT, Horwood LJ. Comorbidity between depressive 
disorders and nicotine dependence in a cohort of 16-year-olds. Archives of general 
psychiatry. 1996;53(11):1043-7. 
65. Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and 
revising the cholinergic hypothesis. Trends Pharmacol Sci. 2010;31(12):580-6. 
66. Carceller-Maicas N, Ariste S, Martinez-Hernaez A, Martorell-Poveda MA, 
Correa-Urquiza M, DiGiacomo SM. [Smoking as a form of self-medication for 
	 82	
depression or anxiety in young adults: results of a mixed-methods study]. Adicciones. 
2014;26(1):34-45. 
67. Wiesbeck GA, Kuhl HC, Yaldizli O, Wurst FM, State WISGoB, Trait Markers 
of Alcohol U, et al. Tobacco smoking and depression--results from the WHO/ISBRA 
study. Neuropsychobiology. 2008;57(1-2):26-31. 
68. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a 
result of 'overspill' of inflammatory mediators from the lungs? Review of the 
evidence. Thorax. 2010;65(10):930-6. 
69. Tayefi M, Shafiee M, Kazemi-Bajestani SMR, Esmaeili H, Darroudi S, 
Khakpouri S, et al. Depression and anxiety both associate with serum level of hs-
CRP: A gender-stratified analysis in a population-based study. 
Psychoneuroendocrinology. 2017;81:63-9. 
70. Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damas JK, et al. 
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort 
Study. The European respiratory journal. 2010;35(3):540-8. 
71. Al-shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of 
systemic inflammation and depression and fatigue in moderate clinically stable 
COPD. Respir Res. 2011;12:3. 
72. Marinho PE, Castro CM, Raposo MC, Guerra RO, de Andrade AD. 
Depressive symptoms, inflammatory markers and body composition in elderly with 
and without chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr. 
2012;54(3):453-8. 
73. van Dijk EJ, Vermeer SE, de Groot JC, van de Minkelis J, Prins ND, Oudkerk 
M, et al. Arterial oxygen saturation, COPD, and cerebral small vessel disease. Journal 
of neurology, neurosurgery, and psychiatry. 2004;75(5):733-6. 
74. Campbell JJ, 3rd, Coffey CE. Neuropsychiatric significance of subcortical 
hyperintensity. The Journal of neuropsychiatry and clinical neurosciences. 
2001;13(2):261-88. 
75. Brown FW, Lewine RJ, Hudgins PA, Risch SC. White matter hyperintensity 
signals in psychiatric and nonpsychiatric subjects. The American journal of 
psychiatry. 1992;149(5):620-5. 
76. Dunlop DD, Lyons JS, Manheim LM, Song J, Chang RW. Arthritis and heart 
disease as risk factors for major depression: the role of functional limitation. Medical 
care. 2004;42(6):502-11. 
	 83	
77. Penninx BW, van Tilburg T, Boeke AJ, Deeg DJ, Kriegsman DM, van Eijk 
JT. Effects of social support and personal coping resources on depressive symptoms: 
different for various chronic diseases? Health psychology : official journal of the 
Division of Health Psychology, American Psychological Association. 
1998;17(6):551-8. 
78. Moylan S, Jacka FN, Pasco JA, Berk M. Cigarette smoking, nicotine 
dependence and anxiety disorders: a systematic review of population-based, 
epidemiological studies. BMC Med. 2012;10:123. 
79. Moylan S, Jacka FN, Pasco JA, Berk M. How cigarette smoking may increase 
the risk of anxiety symptoms and anxiety disorders: a critical review of biological 
pathways. Brain Behav. 2013;3(3):302-26. 
80. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in 
patients with chronic obstructive pulmonary disease (COPD). A review. Nord J 
Psychiatry. 2004;58(1):65-70. 
81. Grassi M, Caldirola D, Vanni G, Guerriero G, Piccinni M, Valchera A, et al. 
Baseline respiratory parameters in panic disorder: a meta-analysis. Journal of 
affective disorders. 2013;146(2):158-73. 
82. Freire RC, Perna G, Nardi AE. Panic disorder respiratory subtype: 
psychopathology, laboratory challenge tests, and response to treatment. Harvard 
review of psychiatry. 2010;18(4):220-9. 
83. Teixeira PJ, Porto L, Kristensen CH, Santos AH, Menna-Barreto SS, Do 
Prado-Lima PA. Post-traumatic stress symptoms and exacerbations in COPD patients. 
COPD. 2015;12(1):90-5. 
84. Stage KB, Middelboe T, Pisinger C. Depression and chronic obstructive 
pulmonary disease (COPD). Impact on survival. Acta Psychiatr Scand. 
2005;111(4):320-3. 
85. Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. 
Comprehensive meta-analysis of excess mortality in depression in the general 
community versus patients with specific illnesses. Am J Psychiatry. 2014;171(4):453-
62. 
86. Kokturk N, Polatli M, Oguzulgen IK, Saleemi S, Al Ghobain M, Khan J, et al. 
Adherence to COPD treatment in Turkey and Saudi Arabia: results of the ADCARE 
study. Int J Chron Obstruct Pulmon Dis. 2018;13:1377-88. 
	 84	
87. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive 
pulmonary disease from attending pulmonary rehabilitation? A systematic review. 
Chron Respir Dis. 2011;8(2):89-99. 
88. Bhandari NJ, Jain T, Marolda C, ZuWallack RL. Comprehensive pulmonary 
rehabilitation results in clinically meaningful improvements in anxiety and depression 
in patients with chronic obstructive pulmonary disease. Journal of cardiopulmonary 
rehabilitation and prevention. 2013;33(2):123-7. 
89. Boutou AK, Tanner RJ, Lord VM, Hogg L, Nolan J, Jefford H, et al. An 
evaluation of factors associated with completion and benefit from pulmonary 
rehabilitation in COPD. BMJ Open Respir Res. 2014;1(1):e000051. 
90. Cassidy S, Turnbull S, Gardani M, Kirkwood K. Attendance at pulmonary 
rehabilitation classes: an exploration of demographic, physiological and psychological 
factors that predict completion of treatment. Chron Respir Dis. 2014;11(2):95-102. 
91. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of anxiety and 
depression on patient adherence. Archives of internal medicine. 2000;160(14):2101-7. 
92. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related 
factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459-
67. 
93. Laurin C, Moullec G, Bacon SL, Lavoie KL. Impact of anxiety and depression 
on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care 
Med. 2012;185(9):918-23. 
94. Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR. 
Associations between chronic comorbidity and exacerbation risk in primary care 
patients with COPD. Respir Res. 2017;18(1):31. 
95. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Platt RW, et al. Independent 
effect of depression and anxiety on chronic obstructive pulmonary disease 
exacerbations and hospitalizations. American journal of respiratory and critical care 
medicine. 2008;178(9):913-20. 
96. Koenig HG, Kuchibhatla M. Use of health services by hospitalized medically 
ill depressed elderly patients. The American journal of psychiatry. 1998;155(7):871-7. 
97. Cohen S, Tyrrell DA, Smith AP. Negative life events, perceived stress, 
negative affect, and susceptibility to the common cold. Journal of personality and 
social psychology. 1993;64(1):131-40. 
	 85	
98. Regvat J, Zmitek A, Vegnuti M, Kosnik M, Suskovic S. Anxiety and 
depression during hospital treatment of exacerbation of chronic obstructive 
pulmonary disease. J Int Med Res. 2011;39(3):1028-38. 
99. Ormel J, Kempen GI, Deeg DJ, Brilman EI, van Sonderen E, Relyveld J. 
Functioning, well-being, and health perception in late middle-aged and older people: 
comparing the effects of depressive symptoms and chronic medical conditions. 
Journal of the American Geriatrics Society. 1998;46(1):39-48. 
100. Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and 
anxiety in chronic heart failure and chronic obstructive pulmonary disease: 
prevalence, relevance, clinical implications and management principles. Int J Geriatr 
Psychiatry. 2010;25(12):1209-21. 
101. Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in 
physical functioning in a sample of the Los Angeles general population. The 
American journal of psychiatry. 1988;145(6):712-7. 
102. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, et al. 
Functional impairment in COPD patients: the impact of anxiety and depression. 
Psychosomatics. 2000;41(6):465-71. 
103. Weaver TE, Richmond TS, Narsavage GL. An explanatory model of 
functional status in chronic obstructive pulmonary disease. Nurs Res. 1997;46(1):26-
31. 
104. Von Korff M, Katon W, Rutter C, Ludman E, Simon G, Lin E, et al. Effect on 
disability outcomes of a depression relapse prevention program. Psychosomatic 
medicine. 2003;65(6):938-43. 
105. Aydin IO, Ulusahin A. Depression, anxiety comorbidity, and disability in 
tuberculosis and chronic obstructive pulmonary disease patients: applicability of 
GHQ-12. Gen Hosp Psychiatry. 2001;23(2):77-83. 
106. Borak J, Chodosowska E, Matuszewski A, Zielinski J. Emotional status does 
not alter exercise tolerance in patients with chronic obstructive pulmonary disease. 
The European respiratory journal. 1998;12(2):370-3. 
107. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that 
influence disease-specific quality of life or health status in patients with COPD: a 
review and meta-analysis of Pearson correlations. Prim Care Respir J. 
2011;20(3):257-68. 
	 86	
108. Duenas-Espin I, Demeyer H, Gimeno-Santos E, Polkey MI, Hopkinson NS, 
Rabinovich RA, et al. Depression symptoms reduce physical activity in COPD 
patients: a prospective multicenter study. Int J Chron Obstruct Pulmon Dis. 
2016;11:1287-95. 
109. Beck JG, Scott S, Teague RB, Perez FI. Correlates of daily impairment in 
COPD. Rehabilitation psychology. 1988;33(2):77-84. 
110. Martinez Rivera C, Costan Galicia J, Alcazar Navarrete B, Garcia-Polo C, 
Ruiz Iturriaga LA, Herrejon A, et al. Factors Associated with Depression in COPD: A 
Multicenter Study. Lung. 2016;194(3):335-43. 
111. Uchmanowicz I, Jankowska-Polanska B, Motowidlo U, Uchmanowicz B, 
Chabowski M. Assessment of illness acceptance by patients with COPD and the 
prevalence of depression and anxiety in COPD. Int J Chron Obstruct Pulmon Dis. 
2016;11:963-70. 
112. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic 
respiratory impairment. Gen Hosp Psychiatry. 1992;14(1):20-8. 
113. Doyle T, Palmer S, Johnson J, Babyak MA, Smith P, Mabe S, et al. 
Association of anxiety and depression with pulmonary-specific symptoms in chronic 
obstructive pulmonary disease. International journal of psychiatry in medicine. 
2013;45(2):189-202. 
114. Borges-Santos E, Wada JT, da Silva CM, Silva RA, Stelmach R, Carvalho 
CR, et al. Anxiety and depression are related to dyspnea and clinical control but not 
with thoracoabdominal mechanics in patients with COPD. Respir Physiol Neurobiol. 
2015;210:1-6. 
115. Tselebis A, Bratis D, Kosmas E, Harikiopoulou M, Theodorakopoulou E, 
Dumitru S, et al. Psychological symptom patterns and vital exhaustion in outpatients 
with chronic obstructive pulmonary disease. Ann Gen Psychiatry. 2011;10:32. 
116. Balcells E, Gea J, Ferrer J, Serra I, Orozco-Levi M, de Batlle J, et al. Factors 
affecting the relationship between psychological status and quality of life in COPD 
patients. Health Qual Life Outcomes. 2010;8:108. 
117. Janssen DJ, Spruit MA, Schols JM, Cox B, Nawrot TS, Curtis JR, et al. 
Predicting changes in preferences for life-sustaining treatment among patients with 
advanced chronic organ failure. Chest. 2012;141(5):1251-9. 
	 87	
118. Meier C, Bodenmann G, Morgeli H, Jenewein J. Dyadic coping, quality of 
life, and psychological distress among chronic obstructive pulmonary disease patients 
and their partners. Int J Chron Obstruct Pulmon Dis. 2011;6:583-96. 
119. Jacome C, Figueiredo D, Gabriel R, Cruz J, Marques A. Predicting anxiety 
and depression among family carers of people with Chronic Obstructive Pulmonary 
Disease. Int Psychogeriatr. 2014;26(7):1191-9. 
120. Li HL, He XL, Liang BM, Zhang HP, Wang Y, Wang G. Anxiety but not 
depression symptoms are associated with greater perceived dyspnea in asthma during 
bronchoconstriction. Allergy and asthma proceedings. 2015;36(6):447-57. 
121. Halimi L, Marin G, Molinari N, Gamez AS, Boissin C, Suehs CM, et al. 
Impact of psychological factors on the health-related quality of life of patients treated 
for pulmonary arterial hypertension. J Psychosom Res. 2018;105:45-51. 
122. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary 
fibrosis patients. The European respiratory journal. 2001;17(5):954-61. 
123. Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, 
Landefeld CS, et al. Depression is a common and chronic comorbidity in patients with 
interstitial lung disease. Respirology. 2012;17(3):525-32. 
124. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a 
clinical decision support model for clinical research and practice. Drug Alcohol 
Depend. 2007;88 Suppl 2:S61-71. 
125. Tang WK, Wong E, Chiu HF, Lum CM, Ungvari GS. Examining item bias in 
the anxiety subscale of the Hospital Anxiety and Depression Scale in patients with 
chronic obstructive pulmonary disease. Int J Methods Psychiatr Res. 2008;17(2):104-
10. 
126. Julian LJ, Gregorich SE, Earnest G, Eisner MD, Chen H, Blanc PD, et al. 
Screening for depression in chronic obstructive pulmonary disease. Copd. 
2009;6(6):452-8. 
127. Cheung G, Patrick C, Sullivan G, Cooray M, Chang CL. Sensitivity and 
specificity of the Geriatric Anxiety Inventory and the Hospital Anxiety and 
Depression Scale in the detection of anxiety disorders in older people with chronic 
obstructive pulmonary disease. Int Psychogeriatr. 2012;24(1):128-36. 
128. Bratas O, Gronning K, Forbord T. Psychometric properties of the Hospital 
Anxiety and Depression Scale and The General Health Questionnaire-20 in COPD 
inpatients. Scand J Caring Sci. 2014;28(2):413-20. 
	 88	
129. Bock K, Bendstrup E, Hilberg O, Lokke A. Screening tools for evaluation of 
depression in Chronic Obstructive Pulmonary Disease (COPD). A systematic review. 
Eur Clin Respir J. 2017;4(1):1332931. 
130. Willgoss TG, Goldbart J, Fatoye F, Yohannes AM. The development and 
validation of the anxiety inventory for respiratory disease. Chest. 2013;144(5):1587-
96. 
131. Yohannes AM, Willgoss TG. The accuracy of the anxiety inventory 
respiratory disease scale for patients with chronic obstructive pulmonary disease. Int J 
Geriatr Psychiatry. 2015;30(1):106-8. 
132. Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric 
morbidity in a difficult asthma population: relationship to asthma outcome. 
Respiratory medicine. 2005;99(9):1152-9. 
133. Plourde A, Moullec G, Bacon SL, Suarthana E, Lavoie KL. Optimizing 
screening for depression among adults with asthma. J Asthma. 2016;53(7):736-43. 
134. Steer RA, Beck AT, Riskind JH, Brown G. Differentiation of depressive 
disorders from generalized anxiety by the Beck Depression Inventory. J Clin Psychol. 
1986;42(3):475-8. 
135. Jani BD, Purves D, Barry S, Cavanagh J, McLean G, Mair FS. Challenges and 
implications of routine depression screening for depression in chronic disease and 
multimorbidity: a cross sectional study. PLoS One. 2013;8(9):e74610. 
136. Gilbody S, Sheldon T, House A. Screening and case-finding instruments for 
depression: a meta-analysis. CMAJ : Canadian Medical Association journal = journal 
de l'Association medicale canadienne. 2008;178(8):997-1003. 
137. Global Initiative for Chronic Obstructive Lung Disease. Management, and 
prevention of chronic obstructive pulmonary disease. Global strategy for the 
diagnosis; 2018; [accessed 20 Oct 2018] Available from: https://goldcopd.org/wp-
content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. 
138. Gilbody S, House AO, Sheldon TA. Screening and case finding instruments 
for depression. The Cochrane database of systematic reviews. 2005(4):CD002792. 
139. Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the Minimal 
Clinically Important Difference for the Hospital Anxiety and Depression Scale in 
Patients With Cardiovascular Disease. J Cardiopulm Rehabil Prev. 2018. 
140. Phan T, Carter O, Adams C, Waterer G, Chung LP, Hawkins M, et al. 
Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression 
	 89	
Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of 
depression and anxiety in patients with chronic obstructive pulmonary disease. Chron 
Respir Dis. 2016;13(3):220-8. 
141. Nowak C, Sievi NA, Clarenbach CF, Schwarz EI, Schlatzer C, Brack T, et al. 
Accuracy of the Hospital Anxiety and Depression Scale for identifying depression in 
chronic obstructive pulmonary disease patients. Pulm Med. 2014;2014:973858. 
142. Willgoss TG, Goldbart J, Fatoye F, Yohannes AM. The development and 
validation of the anxiety inventory for respiratory disease. Chest. 2013;144(5):1587-
96. 
143. Innovative Care for Chronic Conditions: Building Blocks for Action. World 
Health Organization (WHO); 2002; [accessed 20 Oct 2018] Available from: 
https://www.who.int/chp/knowledge/publications/icccreport/en/. 
144. Global Strategy for Asthma Management and Prevention. Global Initiative for 
Asthma (GINA); 2018; [accessed 20 Oct 2018] Available from: www.ginasthma.org. 
145. Deb A, Sambamoorthi U. Depression treatment patterns among adults with 
chronic obstructive pulmonary disease and depression. Curr Med Res Opin. 
2017;33(2):201-8. 
146. Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological 
therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev. 
2018;5:CD010558. 
147. Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, et 
al. COPD-X Australian and New Zealand guidelines for the diagnosis and 
management of chronic obstructive pulmonary disease: 2017 update. Med J Aust. 
2017;207(10):436-42. 
148. Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and 
depression in patients with chronic obstructive pulmonary disease: a literature review. 
Respirology. 2012;17(4):627-38. 
149. Volpato E, Banfi P, Rogers SM, Pagnini F. Relaxation Techniques for People 
with Chronic Obstructive Pulmonary Disease: A Systematic Review and a Meta-
Analysis. Evid Based Complement Alternat Med. 2015;2015:628365. 
150. Pollok J, van Agteren JE, Esterman AJ, Carson-Chahhoud KV. Psychological 
therapies for the treatment of depression in chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev. 2019;3:CD012347. 
	 90	
151. Depression in adults with a chronic physical health problem: recognition and 
management. National Institute for health and care excellence (NICE); 2009; 
[accessed 20 Oct 2018]. Available from: www.nice.org.uk/guidance/cg91. 
152. Usmani ZA, Carson KV, Heslop K, Esterman AJ, De Soyza A, Smith BJ. 
Psychological therapies for the treatment of anxiety disorders in chronic obstructive 
pulmonary disease. Cochrane Database Syst Rev. 2017;3:CD010673. 
153. Vickers A, Zollman C. ABC of complementary medicine. Hypnosis and 
relaxation therapies. Bmj. 1999;319(7221):1346-9. 
154. Lolak S, Connors GL, Sheridan MJ, Wise TN. Effects of progressive muscle 
relaxation training on anxiety and depression in patients enrolled in an outpatient 
pulmonary rehabilitation program. Psychother Psychosom. 2008;77(2):119-25. 
155. Yeh GY, Roberts DH, Wayne PM, Davis RB, Quilty MT, Phillips RS. Tai chi 
exercise for patients with chronic obstructive pulmonary disease: a pilot study. Respir 
Care. 2010;55(11):1475-82. 
156. Donesky-Cuenco D, Nguyen HQ, Paul S, Carrieri-Kohlman V. Yoga therapy 
decreases dyspnea-related distress and improves functional performance in people 
with chronic obstructive pulmonary disease: a pilot study. Journal of alternative and 
complementary medicine. 2009;15(3):225-34. 
157. Mularski RA, Munjas BA, Lorenz KA, Sun S, Robertson SJ, Schmelzer W, et 
al. Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic 
obstructive lung disease. J Altern Complement Med. 2009;15(10):1083-90. 
158. Chan RR, Giardino N, Larson JL. A pilot study: mindfulness meditation 
intervention in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:445-54. 
159. Bonilha AG, Onofre F, Vieira ML, Prado MY, Martinez JA. Effects of singing 
classes on pulmonary function and quality of life of COPD patients. International 
journal of chronic obstructive pulmonary disease. 2009;4:1-8. 
160. Lord VM, Cave P, Hume VJ, Flude EJ, Evans A, Kelly JL, et al. Singing 
teaching as a therapy for chronic respiratory disease--a randomised controlled trial 
and qualitative evaluation. BMC pulmonary medicine. 2010;10:41. 
161. Lord VM, Hume VJ, Kelly JL, Cave P, Silver J, Waldman M, et al. Singing 
classes for chronic obstructive pulmonary disease: a randomized controlled trial. 
BMC pulmonary medicine. 2012;12:69. 
	 91	
162. Vazquez I, Buceta J. Relaxation therapy in the treatment of bronchial asthma: 
effects on basal spirometric values. Psychotherapy and psychosomatics. 
1993;60(2):106-12. 
163. Vedanthan PK, Kesavalu LN, Murthy KC, Duvall K, Hall MJ, Baker S, et al. 
Clinical study of yoga techniques in university students with asthma: a controlled 
study. Allergy and asthma proceedings : the official journal of regional and state 
allergy societies. 1998;19(1):3-9. 
164. Chiang LC, Ma WF, Huang JL, Tseng LF, Hsueh KC. Effect of relaxation-
breathing training on anxiety and asthma signs/symptoms of children with moderate-
to-severe asthma: a randomized controlled trial. International journal of nursing 
studies. 2009;46(8):1061-70. 
165. Holloway EA, West RJ. Integrated breathing and relaxation training (the 
Papworth method) for adults with asthma in primary care: a randomised controlled 
trial. Thorax. 2007;62(12):1039-42. 
166. Pbert L, Madison JM, Druker S, Olendzki N, Magner R, Reed G, et al. Effect 
of mindfulness training on asthma quality of life and lung function: a randomised 
controlled trial. Thorax. 2012;67(9):769-76. 
167. Greenberger D, Padesky CA. Mind Over Mood: A Cognitive Therapy 
Treatment. Manual for Clients. . New York, NY: Guilford Press.; 1995. 
168. Tyrer P, Cooper S, Salkovskis P, Tyrer H, Crawford M, Byford S, et al. 
Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in 
medical patients: a multicentre randomised controlled trial. Lancet. 
2014;383(9913):219-25. 
169. Emery CF, Schein RL, Hauck ER, MacIntyre NR. Psychological and cognitive 
outcomes of a randomized trial of exercise among patients with chronic obstructive 
pulmonary disease. Health Psychol. 1998;17(3):232-40. 
170. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH. A randomized 
controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. 
Respiratory medicine. 2010;104(7):986-94. 
171. Kunik ME, Braun U, Stanley MA, Wristers K, Molinari V, Stoebner D, et al. 
One session cognitive behavioural therapy for elderly patients with chronic 
obstructive pulmonary disease. Psychol Med. 2001;31(4):717-23. 
172. Kunik ME, Veazey C, Cully JA, Souchek J, Graham DP, Hopko D, et al. 
COPD education and cognitive behavioral therapy group treatment for clinically 
	 92	
significant symptoms of depression and anxiety in COPD patients: a randomized 
controlled trial. Psychol Med. 2008;38(3):385-96. 
173. Livermore N, Sharpe L, McKenzie D. Prevention of panic attacks and panic 
disorder in COPD. The European respiratory journal. 2010;35(3):557-63. 
174. de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of 
psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. 
Arch Phys Med Rehabil. 2003;84(8):1154-7. 
175. Luk EK, Gorelik A, Irving L, Khan F. Effectiveness of cognitive behavioural 
therapy in a community-based pulmonary rehabilitation programme: A controlled 
clinical trial. J Rehabil Med. 2017;49(3):264-9. 
176. Hundt NE, Renn BN, Sansgiry S, Petersen NJ, Stanley MA, Kauth MR, et al. 
Predictors of response to brief CBT in patients with cardiopulmonary conditions. 
Health Psychol. 2018;37(9):866-73. 
177. Stiles-Shields C, Kwasny MJ, Cai X, Mohr DC. Therapeutic Alliance in Face-
to-Face and Telephone-Administered Cognitive Behavioral Therapy. Journal of 
consulting and clinical psychology. 2014. 
178. Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, et al. 
Telephone-administered psychotherapy for depression. Archives of general 
psychiatry. 2005;62(9):1007-14. 
179. Mohr DC, Vella L, Hart S, Heckman T, Simon G. The Effect of Telephone-
Administered Psychotherapy on Symptoms of Depression and Attrition: A Meta-
Analysis. Clinical psychology : a publication of the Division of Clinical Psychology 
of the American Psychological Association. 2008;15(3):243-53. 
180. Veazey C, Cook KF, Stanley M, Lai EC, Kunik ME. Telephone-administered 
cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's 
disease. Journal of clinical psychology in medical settings. 2009;16(3):243-53. 
181. Watson M, White C, Davolls S, Mohammed A, Lynch A, Mohammed K. 
Problem-focussed interactive telephone therapy for cancer patients: a phase II 
feasibility trial. Psycho-oncology. 2013;22(7):1485-91. 
182. Moayeri F, Dunt D, Hsueh YA, Doyle C. Cost-utility analysis of telephone-
based cognitive behavior therapy in chronic obstructive pulmonary disease (COPD) 
patients with anxiety and depression comorbidities: an application for willingness to 
accept concept. Expert Rev Pharmacoecon Outcomes Res. 2018:1-10. 
	 93	
183. Andersson G. Guided internet treatment for anxiety disorders. As effective as 
face-to-face therapies? Studies in health technology and informatics. 2012;181:3-7. 
184. Mansson KN, Skagius Ruiz E, Gervind E, Dahlin M, Andersson G. 
Development and initial evaluation of an internet-based support system for face-to-
face cognitive behavior therapy: a proof of concept study. Journal of medical Internet 
research. 2013;15(12):e280. 
185. Cuijpers P, Donker T, van Straten A, Li J, Andersson G. Is guided self-help as 
effective as face-to-face psychotherapy for depression and anxiety disorders? A 
systematic review and meta-analysis of comparative outcome studies. Psychological 
medicine. 2010;40(12):1943-57. 
186. Cooney P, Jackman C, Coyle D, O'Reilly G. Computerised cognitive-
behavioural therapy for adults with intellectual disability: randomised controlled trial. 
Br J Psychiatry. 2017;211(2):95-102. 
187. Lamers F, Jonkers CC, Bosma H, Chavannes NH, Knottnerus JA, van Eijk JT. 
Improving quality of life in depressed COPD patients: effectiveness of a minimal 
psychological intervention. COPD. 2010;7(5):315-22. 
188. Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of 
behavioural treatment of depression. Psychological medicine. 2008;38(5):611-23. 
189. Farver-Vestergaard I, O'Toole MS, O'Connor M, Lokke A, Bendstrup E, 
Basdeo SA, et al. Mindfulness-based cognitive therapy in COPD: a cluster 
randomised controlled trial. The European respiratory journal. 2018;51(2). 
190. Pateraki E, Morris PG. Effectiveness of cognitive behavioural therapy in 
reducing anxiety in adults and children with asthma: A systematic review. J Asthma. 
2018;55(5):532-54. 
191. Yorke J, Adair P, Doyle AM, Dubrow-Marshall L, Fleming S, Holmes L, et al. 
A randomised controlled feasibility trial of Group Cognitive Behavioural Therapy for 
people with severe asthma. J Asthma. 2017;54(5):543-54. 
192. Jonker AA, Comijs HC, Knipscheer KC, Deeg DJ. Promotion of self-
management in vulnerable older people: a narrative literature review of outcomes of 
the Chronic Disease Self-Management Program (CDSMP). European journal of 
ageing. 2009;6(4):303-14. 
193. Effing T, Monninkhof EM, van der Valk PD, van der Palen J, van Herwaarden 
CL, Partidge MR, et al. Self-management education for patients with chronic 
	 94	
obstructive pulmonary disease. The Cochrane database of systematic reviews. 
2007(4):CD002990. 
194. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. 
Reduction of hospital utilization in patients with chronic obstructive pulmonary 
disease: a disease-specific self-management intervention. Archives of internal 
medicine. 2003;163(5):585-91. 
195. McLaughlin TJ, Aupont O, Bambauer KZ, Stone P, Mullan MG, Colagiovanni 
J, et al. Improving psychologic adjustment to chronic illness in cardiac patients. The 
role of depression and anxiety. Journal of general internal medicine. 
2005;20(12):1084-90. 
196. Kaptein AA, Scharloo M, Fischer MJ, Snoei L, Hughes BM, Weinman J, et al. 
50 years of psychological research on patients with COPD--road to ruin or highway to 
heaven? Respiratory medicine. 2009;103(1):3-11. 
197. Lenferink A, Brusse-Keizer M, van der Valk PD, Frith PA, Zwerink M, 
Monninkhof EM, et al. Self-management interventions including action plans for 
exacerbations versus usual care in patients with chronic obstructive pulmonary 
disease. Cochrane Database Syst Rev. 2017;8:CD011682. 
198. Robinson A, Courtney-Pratt H, Lea E, Cameron-Tucker H, Turner P, 
Cummings E, et al. Transforming clinical practice amongst community nurses: 
mentoring for COPD patient self-management. Journal of clinical nursing. 2008. 
199. Wood-Baker R, Reid D, Robinson A, Walters EH. Clinical trial of community 
nurse mentoring to improve self-management in patients with chronic obstructive 
pulmonary disease. International journal of chronic obstructive pulmonary disease. 
2012;7:407-13. 
200. Walters J, Cameron-Tucker H, Wills K, Schuz N, Scott J, Robinson A, et al. 
Effects of telephone health mentoring in community-recruited chronic obstructive 
pulmonary disease on self-management capacity, quality of life and psychological 
morbidity: a randomised controlled trial. BMJ open. 2013;3(9):e003097. 
201. Effing T, Kerstjens H, van der Valk P, Zielhuis G, van der Palen J. (Cost)-
effectiveness of self-treatment of exacerbations on the severity of exacerbations in 
patients with COPD: the COPE II study. Thorax. 2009;64(11):956-62. 
202. Schuz N, Walters JA, Cameron-Tucker H, Scott J, Wood-Baker R, Walters 
EH. Patient Anxiety and Depression Moderate the Effects of Increased Self-
management Knowledge on Physical Activity: A Secondary Analysis of a 
	 95	
Randomised Controlled Trial on Health-Mentoring in COPD. COPD. 2015;12(5):502-
9. 
203. Denford S, Taylor RS, Campbell JL, Greaves CJ. Effective behavior change 
techniques in asthma self-care interventions: systematic review and meta-regression. 
Health psychology : official journal of the Division of Health Psychology, American 
Psychological Association. 2014;33(7):577-87. 
204. Lavoie KL, Moullec G, Lemiere C, Blais L, Labrecque M, Beauchesne MF, et 
al. Efficacy of brief motivational interviewing to improve adherence to inhaled 
corticosteroids among adult asthmatics: results from a randomized controlled pilot 
feasibility trial. Patient preference and adherence. 2014;8:1555-69. 
205. Kelly C, Grundy S, Lynes D, Evans DJ, Gudur S, Milan SJ, et al. Self-
management for bronchiectasis. Cochrane Database Syst Rev. 2018;2:CD012528. 
206. Huhn M, Tardy M, Spineli LM, Kissling W, Forstl H, Pitschel-Walz G, et al. 
Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders: A 
Systematic Overview of Meta-analyses. JAMA psychiatry. 2014. 
207. Usmani ZA, Carson KV, Cheng JN, Esterman AJ, Smith BJ. Pharmacological 
interventions for the treatment of anxiety disorders in chronic obstructive pulmonary 
disease. The Cochrane database of systematic reviews. 2011(11):CD008483. 
208. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M. 
Antidepressants for depression in physically ill people. The Cochrane database of 
systematic reviews. 2010(3):CD007503. 
209. Evans M, Hammond M, Wilson K, Lye M, Copeland J. Placebo-controlled 
treatment trial of depression in elderly physically ill patients. International journal of 
geriatric psychiatry. 1997;12(8):817-24. 
210. Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in 
older patients with chronic obstructive pulmonary disease: impact on the course of the 
disease and health outcomes. Drugs Aging. 2014;31(7):483-92. 
211. Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and 
treatment of anxiety disorders. P & T : a peer-reviewed journal for formulary 
management. 2013;38(1):30-57. 
212. He Y, Zheng Y, Xu C, Yang H, Wang Z, Zhou L, et al. Sertraline 
hydrochloride treatment for patients with stable chronic obstructive pulmonary 
disease complicated with depression: a randomized controlled trial. Clin Respir J. 
2016;10(3):318-25. 
	 96	
213. Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of 
paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004;61(3):140-7. 
214. Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression 
on quality-of-life and exercise tolerance in severe COPD. COPD. 2005;2(2):233-41. 
215. Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of 
antidepressant drug therapy in depressed elderly patients with chronic obstructive 
pulmonary disease. Int J Geriatr Psychiatry. 2001;16(5):451-4. 
216. Vozoris NT, Wang X, Austin PC, Stephenson AL, O'Donnell DE, Gershon 
AS, et al. Serotonergic antidepressant use and morbidity and mortality among older 
adults with COPD. The European respiratory journal. 2018;52(1). 
217. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, 
VanTuinen C. Improvement in mood, physical symptoms, and function with 
nortriptyline for depression in patients with chronic obstructive pulmonary disease. 
Psychosomatics. 1992;33(2):190-201. 
218. Light RW, Merrill EJ, Despars J, Gordon GH, Mutalipassi LR. Doxepin 
treatment of depressed patients with chronic obstructive pulmonary disease. Archives 
of internal medicine. 1986;146(7):1377-80. 
219. Strom K, Boman G, Pehrsson K, Alton M, Singer J, Rydstrom PO, et al. 
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive 
pulmonary disease. The European respiratory journal. 1995;8(3):425-9. 
220. Yohannes AM, Connolly MJ. Do antidepressants work in patients with 
chronic obstructive pulmonary disease with comorbid depression? Expert Rev Respir 
Med. 2011;5(6):727-9. 
221. Singh NP, Despars JA, Stansbury DW, Avalos K, Light RW. Effects of 
buspirone on anxiety levels and exercise tolerance in patients with chronic airflow 
obstruction and mild anxiety. Chest. 1993;103(3):800-4. 
222. Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clinical medicine 
insights Circulatory, respiratory and pulmonary medicine. 2013;7:17-34. 
223. Brown ES, Vigil L, Khan DA, Liggin JD, Carmody TJ, Rush AJ. A 
randomized trial of citalopram versus placebo in outpatients with asthma and major 
depressive disorder: a proof of concept study. Biol Psychiatry. 2005;58(11):865-70. 
224. Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe 
asthma and major depressive disorder: a randomized, double-blind, placebo-
controlled proof-of-concept study. Psychosomatics. 2012;53(1):75-80. 
	 97	
225. Brown ES, Vornik LA, Khan DA, Rush AJ. Bupropion in the treatment of 
outpatients with asthma and major depressive disorder. Int J Psychiatry Med. 
2007;37(1):23-8. 
226. Melien O, Skaali T, Myhr K, Brors O. Venlafaxine and asthma. Nordic journal 
of psychiatry. 2005;59(6):538-40. 
227. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, et al. 
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice 
Guidelines. Chest. 2007;131(5 Suppl):4S-42S. 
228. Coleman PG, Philp I, Mullee MA. Does the use of the Geriatric Depression 
Scale make redundant the need for separate measures of well-being on geriatrics 
wards? Age and ageing. 1995;24(5):416-20. 
229. Bhandari NJ, Jain T, Marolda C, ZuWallack RL. Comprehensive pulmonary 
rehabilitation results in clinically meaningful improvements in anxiety and depression 
in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 
2013;33(2):123-7. 
230. Pierobon A, Sini Bottelli E, Ranzini L, Bruschi C, Maestri R, Bertolotti G, et 
al. COPD patients' self-reported adherence, psychosocial factors and mild cognitive 
impairment in pulmonary rehabilitation. Int J Chron Obstruct Pulmon Dis. 
2017;12:2059-67. 
231. Garrod R, Marshall J, Barley E, Jones PW. Predictors of success and failure in 
pulmonary rehabilitation. The European respiratory journal. 2006;27(4):788-94. 
232. Bodescu MM, Turcanu AM, Gavrilescu MC, Mihaescu T. Respiratory 
rehabilitation in healing depression and anxiety in COPD patients. Pneumologia. 
2015;64(4):14-8. 
233. von Leupoldt A, Taube K, Lehmann K, Fritzsche A, Magnussen H. The 
impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients 
with COPD. Chest. 2011;140(3):730-6. 
234. Harris D, Hayter M, Allender S. Improving the uptake of pulmonary 
rehabilitation in patients with COPD: qualitative study of experiences and attitudes. 
Br J Gen Pract. 2008;58(555):703-10. 
235. Pirraglia PA, Casserly B, Velasco R, Borgia ML, Nici L. Association of 
change in depression and anxiety symptoms with functional outcomes in pulmonary 
rehabilitation patients. J Psychosom Res. 2011;71(1):45-9. 
	 98	
236. Trappenburg JC, Troosters T, Spruit MA, Vandebrouck N, Decramer M, 
Gosselink R. Psychosocial conditions do not affect short-term outcome of 
multidisciplinary rehabilitation in chronic obstructive pulmonary disease. Arch Phys 
Med Rehabil. 2005;86(9):1788-92. 
237. Withers NJ, Rudkin ST, White RJ. Anxiety and depression in severe chronic 
obstructive pulmonary disease: the effects of pulmonary rehabilitation. J Cardiopulm 
Rehabil. 1999;19(6):362-5. 
238. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, et al. 
British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 
2013;68 Suppl 2:ii1-30. 
239. Wiles L, Cafarella P, Williams MT. Exercise training combined with 
psychological interventions for people with chronic obstructive pulmonary disease. 
Respirology. 2015;20(1):46-55. 
240. Williams MT, Cafarella P, Paquet C, Frith P. Cognitive Behavioral Therapy 
for Management of Dyspnea: A Pilot Study. Respir Care. 2015;60(9):1303-13. 
241. Agbetile J, Singh S, Bradding P, Pavord I, Green R. P147. Outcomes of 
pulmonary rehabilitation in severe asthma. Thorax. 2011;66(4):A127. 
242. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of 
pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil. 
2006;26(4):237-43. 
243. Kenn K, Gloeckl R, Behr J. Pulmonary rehabilitation in patients with 
idiopathic pulmonary fibrosis--a review. Respiration; international review of thoracic 
diseases. 2013;86(2):89-99. 
244. Deniz S, Sahin H, Yalniz E. Does the severity of interstitial lung disease affect 
the gains from pulmonary rehabilitation? Clin Respir J. 2018. 
245. Mandal P, Sidhu MK, Kope L, Pollock W, Stevenson LM, Pentland JL, et al. 
A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest 
physiotherapy alone in bronchiectasis. Respiratory medicine. 2012;106(12):1647-54. 
246. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle 
training in patients with bronchiectasis. Thorax. 2005;60(11):943-8. 
247. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An 
official American Thoracic Society/European Respiratory Society statement: key 
concepts and advances in pulmonary rehabilitation. American journal of respiratory 
and critical care medicine. 2013;188(8):e13-64. 
	 99	
248. Caldera-Alvarado G, Khan DA, Defina LF, Pieper A, Brown ES. Relationship 
between asthma and cognition: the Cooper Center Longitudinal Study. Allergy. 
2013;68(4):545-8. 
249. Irani F, Barbone JM, Beausoleil J, Gerald L. Is asthma associated with 
cognitive impairments? A meta-analytic review. J Clin Exp Neuropsychol. 
2017;39(10):965-78. 
250. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. The European 
respiratory journal. 2010;35(4):913-22. 
251. Bors M, Tomic R, Perlman DM, Kim HJ, Whelan TP. Cognitive function in 
idiopathic pulmonary fibrosis. Chron Respir Dis. 2015;12(4):365-72. 
252. Pierobon A, Ranzini L, Torlaschi V, Sini Bottelli E, Giardini A, Bruschi C, et 
al. Screening for neuropsychological impairment in COPD patients undergoing 
rehabilitation. PLoS One. 2018;13(8):e0199736. 
253. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory 
loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 
2003;18(10):951-9. 
254. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: 
possible implications for functional neuropathology. Br J Psychiatry. 2001;178:200-6. 
255. Porter RJ, Robinson LJ, Malhi GS, Gallagher P. The neurocognitive profile of 
mood disorders - a review of the evidence and methodological issues. Bipolar Disord. 
2015;17 Suppl 2:21-40. 
256. Groves SJ, Douglas KM, Porter RJ. A Systematic Review of Cognitive 
Predictors of Treatment Outcome in Major Depression. Front Psychiatry. 2018;9:382. 
257. Morimoto SS, Gunning FM, Wexler BE, Hu W, Ilieva I, Liu J, et al. Executive 
Dysfunction Predicts Treatment Response to Neuroplasticity-Based Computerized 
Cognitive Remediation (nCCR-GD) in Elderly Patients with Major Depression. Am J 
Geriatr Psychiatry. 2016;24(10):816-20. 
258. Cleutjens F, Spruit MA, Ponds R, Vanfleteren L, Franssen FME, Dijkstra JB, 
et al. The Impact of Cognitive Impairment on Efficacy of Pulmonary Rehabilitation in 
Patients With COPD. J Am Med Dir Assoc. 2017;18(5):420-6. 
259. Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-
Mental State Examination compared with the traditional Mini-Mental State 
Examination. Am J Psychiatry. 1991;148(1):102-5. 
	 100	
260. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State 
Examination. Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50. 
261. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin 
I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild 
cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-9. 
262. Joosten-Weyn Banningh LW, Prins JB, Vernooij-Dassen MJ, Wijnen HH, 
Olde Rikkert MG, Kessels RP. Group therapy for patients with mild cognitive 
impairment and their significant others: results of a waiting-list controlled trial. 
Gerontology. 2011;57(5):444-54. 
263. Joosten-Weyn Banningh LW, Roelofs SC, Vernooij-Dassen MJ, Prins JB, 
Olde Rikkert MG, Kessels RP. Long-term effects of group therapy for patients with 
mild cognitive impairment and their significant others: a 6- to 8-month follow-up 
study. Dementia (London). 2013;12(1):81-91. 
264. Hassiotis A, Serfaty M, Azam K, Strydom A, Blizard R, Romeo R, et al. 
Manualised Individual Cognitive Behavioural Therapy for mood disorders in people 
with mild to moderate intellectual disability: a feasibility randomised controlled trial. 
J Affect Disord. 2013;151(1):186-95. 
265. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure 
of health status for chronic airflow limitation. The St. George's Respiratory 
Questionnaire. The American review of respiratory disease. 1992;145(6):1321-7. 
266. Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R. Validity of the 
Saint George's Respiratory Questionnaire in the evaluation of the health-related 
quality of life in patients with interstitial lung disease secondary to systemic sclerosis. 
Rheumatology. 2007;46(2):296-301. 
267. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. 
George's Respiratory Questionnaire in bronchiectasis. American journal of respiratory 
and critical care medicine. 1997;156(2 Pt 1):536-41. 
268. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of 
clinical methods used to evaluate dyspnea in patients with chronic obstructive 
pulmonary disease. American journal of respiratory and critical care medicine. 
1998;158(4):1185-9. 
269. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD: 
more than just the FEV1. Respiratory medicine. 2008;102 Suppl 1:S27-35. 
	 101	
270. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et 
al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in 
chronic obstructive pulmonary disease. The New England journal of medicine. 
2004;350(10):1005-12. 
271. Dressendorfer R, Haykowsky M, Eves N. Exercise for Persons with Chronic 
Obstructive Pulmonary Disease. Current comment by the American College of Sports 
Medicine; 2014; [accessed 16 Jan 2014] Available from: http://www.acsm.org. 
272. Bailey PH. The dyspnea-anxiety-dyspnea cycle--COPD patients' stories of 
breathlessness: "It's scary /when you can't breathe". Qual Health Res. 2004;14(6):760-
78. 
273. Padesky CA, Mooney KA. Clinical tip: Presenting the cognitive model to 
clients. International Cognitive Therapy Newsletter, 6, 13-14 Retrieved from 
wwwpadeskycom. 1990. 
274. Singh VP, Rao V, V P, R CS, K KP. Comparison of the effectiveness of music 
and progressive muscle relaxation for anxiety in COPD--A randomized controlled 
pilot study. Chron Respir Dis. 2009;6(4):209-16. 
275. State of Queensland (Queensland Health) TALF. Better living with Chronic 
Obstructive Pulmonary Disease: A patient guide. 2012. 
276. Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, et al. 
Minimal clinically important difference on the Beck Depression Inventory--II 
according to the patient's perspective. Psychol Med. 2015;45(15):3269-79. 
277. van Manen JG, Bindels PJ, CJ IJ, van der Zee JS, Bottema BJ, Schade E. 
Prevalence of comorbidity in patients with a chronic airway obstruction and controls 
over the age of 40. J Clin Epidemiol. 2001;54(3):287-93. 
278. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation 
improves depression, anxiety, dyspnea and health status in patients with COPD. Am J 
Phys Med Rehabil. 2007;86(1):30-6. 
279. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et 
al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a 
randomised controlled trial. Lancet. 2000;355(9201):362-8. 
280. Walsh JR, McKeough ZJ, Morris NR, Chang AT, Yerkovich ST, Seale HE, et 
al. Metabolic disease and participant age are independent predictors of response to 
pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2013;33(4):249-56. 
	 102	
281. Walsh JR, Morris NR, McKeough ZJ, Yerkovich ST, Paratz JD. A simple 
clinical measure of quadriceps muscle strength identifies responders to pulmonary 
rehabilitation. Pulm Med. 2014;2014:782702. 
282. Vagaggini B, Costa F, Antonelli S, De Simone C, De Cusatis G, Martino F, et 
al. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in 
patients with COPD. Respiratory medicine. 2009;103(8):1224-30. 
283. Coquart JB, Le Rouzic O, Racil G, Wallaert B, Grosbois JM. Real-life 
feasibility and effectiveness of home-based pulmonary rehabilitation in chronic 
obstructive pulmonary disease requiring medical equipment. Int J Chron Obstruct 
Pulmon Dis. 2017;12:3549-56. 
 
 
  
	 103	
Appendix: 
Appendix 1: 
BETTER BREATHING PROGRAM. 
Monday 24th September to Friday 16th November 2018 
Tutorial Rooms:  2 - 10.00am - 12.00pm 
     
Week 1 Monday 24 Sept Introduction/Anatomy and your lung 
condition 
Physiotherapist  
 Friday 
 
28 Sept Breathlessness/How do you breathe & 
Exercise and its benefits/Spirometry 
Physiotherapist  
     
Week 2 Monday 
 
1 Oct PUBLIC HOLIDAY  
 Friday 5 Oct Living with Chronic Lung Disease 
Social Worker 
     
Week 3 Monday 8 Oct Medical Management of Respiratory 
Conditions 
Doctor 
 Friday 12 Oct Problem Solving 
Psychologist  
     
Week 4 Monday 15 Oct Effective Use of Inhaler Devices 
Clinical Nurse Consultant  
  Friday 19 Oct Anxiety and Depression in Chronic Lung 
Disease 
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Psychologist 
     
Week 5 Monday 22 Oct Good Eating Guide 
Dietician 
   Friday 26 Oct Speech Therapy 
Speech Pathologist (approx 45min) 
Community Support 
Community Liaison Nurse (approx 
15min) 
    
Week 6 Monday 29 Oct Triggers and Action Plans for Flare Ups 
Clinical Nurse Consultant 
 Friday 2 Nov Staying Active – Session 1 
Occupational Therapist 
    
Week 7 Monday 5 Nov No education session 
Patients to arrive at 11am for exercise 
 Friday 9 Nov Session 2: Stress Management and 
Relaxation 
Occupational Therapist 
    
 Week 8 Monday 12 Nov Drugs and Your Condition  
Pharmacist 
 Friday  16 Nov Assessment and Program Wrap Up 
Physiotherapist 
    
 
 
